var title_f33_27_34224="Hemoclips after polypectomy";
var content_f33_27_34224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Use of hemoclips after colonic polypectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Large sessile polyp in the right colon in a patient who requires Warfarin anticoagulation; (B) Polypectomy site after polyp removal; (C) Polypectomy defect closed with clips to ensure against further bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34224=[""].join("\n");
var outline_f33_27_34224=null;
var title_f33_27_34225="Patient information: Costochondritis (The Basics)";
var content_f33_27_34225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17109\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/38/30309\">",
"         Costochrondritis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Costochondritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/costochondritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16326252\">",
"      <span class=\"h1\">",
"       What is costochondritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Costochondritis is a condition that causes pain and tenderness in your chest. The pain happens in an area called the costosternal joints, where the ribs meet the breastbone (",
"      <a class=\"graphic graphic_figure graphicRef72179 \" href=\"mobipreview.htm?29/38/30309\">",
"       figure 1",
"      </a>",
"      ). The pain from costochondritis affects only a small area and does not get worse when you move around.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326267\">",
"      <span class=\"h1\">",
"       What causes costochondritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, doctors don&rsquo;t know why people get costochondritis. But in some people, it seems to be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A blow to the chest",
"       </li>",
"       <li>",
"        Heavy lifting or hard exercise",
"       </li>",
"       <li>",
"        An illness that causes you to cough and sneeze",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326282\">",
"      <span class=\"h1\">",
"       What are the symptoms of costochondritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain and tenderness in the chest &ndash; The pain can be sharp, or it might be dull and gnawing",
"       </li>",
"       <li>",
"        Pain when you take a deep breath",
"       </li>",
"       <li>",
"        Pain when you cough",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326297\">",
"      <span class=\"h1\">",
"       Is there a test for costochondritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. Sometimes, he or she might do other tests to make sure you do not have a different problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326312\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people feel better if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do stretching exercises",
"       </li>",
"       <li>",
"        Put a heating pad on the painful area a few times a day.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326327\">",
"      <span class=\"h1\">",
"       How is costochondritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, costochondritis goes away without treatment.",
"     </p>",
"     <p>",
"      Over-the-counter medicines to ease pain include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain-relieving creams that have",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/41/36500?source=see_link\">",
"         capsaicin",
"        </a>",
"        or salicylates in them",
"       </li>",
"       <li>",
"        Pain-relieving pills such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand name: Advil&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might prescribe medicines that ease pain, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        1%",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/60/41920?source=see_link\">",
"         diclofenac",
"        </a>",
"        gel (sample brand name Voltaren&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/23/33140?source=see_link\">",
"         Cyclobenzaprine",
"        </a>",
"        (sample brand name Flexeril&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/17/32021?source=see_link\">",
"         Amitriptyline",
"        </a>",
"        (sample brand name Elavil&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326342\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/27/34225?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17109 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34225=[""].join("\n");
var outline_f33_27_34225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326252\">",
"      What is costochondritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326267\">",
"      What causes costochondritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326282\">",
"      What are the symptoms of costochondritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326297\">",
"      Is there a test for costochondritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326312\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326327\">",
"      How is costochondritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326342\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/38/30309\">",
"      Costochrondritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34226="Clinical pathological cases in gastroenterology: Stomach";
var content_f33_27_34226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical pathological cases in gastroenterology: Stomach",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34226/contributors\">",
"     Andres Gelrud, MD, MMSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34226/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/27/34226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following cases are meant to illustrate clinical, pathological, and endoscopic findings in patients with a variety of gastric conditions. Detailed discussions on the specific disorders are presented on corresponding topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARCINOID",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 70 year old man underwent an upper endoscopy for the evaluation of a two day history of melena and new onset dizziness. The patient's only medical problem is rheumatoid arthritis treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    over the past three years. His weight has been stable and he denies having fevers, nausea, vomiting, abdominal pain, or hematochezia. An upper endoscopy revealed the following (",
"    <a class=\"graphic graphic_picture graphicRef53130 \" href=\"mobipreview.htm?40/54/41825\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65970 \" href=\"mobipreview.htm?38/46/39655\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     B CELL LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 45 year old man with no significant past medical history underwent an upper endoscopy and colonoscopy for the evaluation of iron deficiency anemia and nonspecific abdominal pain. The endoscopy revealed a single 2 cm by 3 cm ulcerated lesion of malignant appearance in the stomach body (",
"    <a class=\"graphic graphic_picture graphicRef51705 \" href=\"mobipreview.htm?33/45/34512\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59389 \" href=\"mobipreview.htm?2/52/2888\">",
"     picture 4",
"    </a>",
"    ). The colonoscopy was normal to the terminal ileum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FUNDIC GLAND POLYP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 52 year old woman underwent an upper endoscopy for the evaluation of persistent acid reflux and epigastric abdominal discomfort. The patient's only medical condition is gastroesophageal reflux disease for which she takes a proton pump inhibitor. Endoscopy revealed a small polyp in the gastric fundus (",
"    <a class=\"graphic graphic_picture graphicRef57827 \" href=\"mobipreview.htm?15/62/16367\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77794 \" href=\"mobipreview.htm?38/58/39843\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2361?source=see_link\">",
"     \"Gastric polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     XANTHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 56 year old male underwent an upper endoscopy for the evaluation of worsening heartburn and nausea. Upper endoscopy revealed two small 4 mm yellow nodules in the fundus (",
"    <a class=\"graphic graphic_picture graphicRef71422 \" href=\"mobipreview.htm?22/24/22927\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51475 \" href=\"mobipreview.htm?35/11/36022\">",
"     picture 8",
"    </a>",
"    ); the esophagus and duodenum were normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL STROMAL TUMOR (GIST)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 68 year old man underwent an upper endoscopy for the evaluation of hematemesis. Upper endoscopy revealed one actively oozing 20 mm by 30 mm submucosal mass in the stomach body; the esophagus and duodenum were normal. Bleeding was controlled after injection of 1:10,000 epinephrine and bipolar electrocautery (",
"    <a class=\"graphic graphic_picture graphicRef52275 \" href=\"mobipreview.htm?9/22/9570\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61000 \" href=\"mobipreview.htm?3/11/3256\">",
"     picture 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SIGNET RING CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 54 year old man presented to his primary care physician complaining of early satiety and unintentional 10 lb weight loss over the past two months. An upper endoscopy revealed diffuse gastric wall thickening with poor distention of the gastric lumen when air was insufflated, suggestive of an infiltrative process (",
"    <a class=\"graphic graphic_picture graphicRef70374 \" href=\"mobipreview.htm?36/51/37681\">",
"     picture 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79482 \" href=\"mobipreview.htm?19/51/20280\">",
"     picture 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MALT LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 50 year old Chinese woman with no significant past medical history presented to her primary care physician complaining of increased frequency of epigastric abdominal pain. She denies any fever, nausea, vomiting, weight loss, fatigue, diarrhea, changes in bowel habits, and has a good appetite and level of energy. She takes no medications and denies any alcohol or tobacco use. The patient is concerned because a sister, who lived in China, died at age 53 of gastric cancer. Her physical examination and laboratory data were all unrevealing. Her work-up included a colonoscopy (normal to the terminal ileum) and upper endoscopy that revealed a superficial ulceration with mucosal thickening in the incisura with surrounding erythema (",
"    <a class=\"graphic graphic_picture graphicRef81847 \" href=\"mobipreview.htm?30/41/31376\">",
"     picture 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61021 \" href=\"mobipreview.htm?14/62/15336\">",
"     picture 14",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2619 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34226=[""].join("\n");
var outline_f33_27_34226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARCINOID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      B CELL LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FUNDIC GLAND POLYP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      XANTHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GASTROINTESTINAL STROMAL TUMOR (GIST)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SIGNET RING CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MALT LYMPHOMA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2619|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/54/41825\" title=\"picture 1\">",
"      Gastric carcinoid CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/46/39655\" title=\"picture 2\">",
"      Gastric carcinoid CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/45/34512\" title=\"picture 3\">",
"      Gastric B cell lymphoma CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/52/2888\" title=\"picture 4\">",
"      Gastric B cell lymphoma CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/62/16367\" title=\"picture 5\">",
"      Fundic gland polyp CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/58/39843\" title=\"picture 6\">",
"      Fundic gland polyps CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/24/22927\" title=\"picture 7\">",
"      Gastric xanthoma CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/11/36022\" title=\"picture 8\">",
"      Gastric xanthoma CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/22/9570\" title=\"picture 9\">",
"      Gastrointestinal stromal tumor CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/11/3256\" title=\"picture 10\">",
"      Gastrointestinal stromal tumor CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/51/37681\" title=\"picture 11\">",
"      Signet ring cancer CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/51/20280\" title=\"picture 12\">",
"      Signet ring cancer CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/41/31376\" title=\"picture 13\">",
"      Gastric MALT lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/62/15336\" title=\"picture 14\">",
"      Gastric MALT lymphoma Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2361?source=related_link\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34227="Crofelemer: Patient drug information";
var content_f33_27_34227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Crofelemer: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/56/21379?source=see_link\">",
"     see \"Crofelemer: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16328253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194744",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea) in patients on HIV drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16328252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to crofelemer or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16328256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16328257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16328258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16328254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16328255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16328259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from water. Do not store in a bathroom or kitchen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16328260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88615 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34227=[""].join("\n");
var outline_f33_27_34227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328253\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328252\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328256\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328257\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328258\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328254\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328255\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328259\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328260\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/56/21379?source=related_link\">",
"      Crofelemer: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34228="Osteo in hip prosthesis";
var content_f33_27_34228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis in the setting of hip prosthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Coronal reformatted CT image demonstrates marked beam hardening artifact about a metallic left hip prosthesis (white arrow). B) Despite extensive artifact in image A, on lung windows a region of air can be identified adjacent to the lesser trochanter (white arrow). C) Fluoroscopic guided aspiration (white arrow indicates needle) yielded 3 cc of pus. Initial gram stain was positive for gram negative rods; cultures subsequently grew Bacteroides fragilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Perry Horwich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34228=[""].join("\n");
var outline_f33_27_34228=null;
var title_f33_27_34229="Seizures in adults";
var content_f33_27_34229=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Seizures in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/27/34229/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34229/contributors\" id=\"au3445\">",
"       Steven C Schachter, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/27/34229/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34229/contributors\" id=\"se6945\">",
"       Timothy A Pedley, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/27/34229/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34229/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34229/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/27/34229?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      WHAT IS A SEIZURE?",
"     </span>",
"    </p>",
"    <p>",
"     The brain contains billions of neurons (nerve cells) that create and receive electrical impulses. Electrical impulses allow neurons to communicate with one another. During a seizure, there is abnormal and excessive electrical activity in the brain. This can cause changes in awareness, behavior,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     abnormal movements. This activity usually lasts only a few seconds to minutes.",
"    </p>",
"    <p>",
"     Epilepsy refers to a condition in which a person has a risk of recurring epileptic seizures. Not everyone who has had a seizure has epilepsy. Nonepileptic seizures can be caused by other conditions such as low blood sugar, a fainting spell, or an anxiety attack.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SEIZURE SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H208217\">",
"     <span class=\"h2\">",
"      Seizure types",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the most common seizure types is a convulsion. This may be called a \"tonic clonic\" or \"grand mal\" seizure. In this type of seizure, a person may stiffen and have jerking muscle movements; during the muscle-jerking, the person may bite their tongue, causing bleeding or frothing at the mouth.",
"    </p>",
"    <p>",
"     Other seizure types are less dramatic. Shaking movements may be isolated to one arm or part of the face. Alternatively, the person may suddenly stop responding and stare for a few seconds, sometimes with chewing motions or smacking the lips.",
"    </p>",
"    <p>",
"     Seizures may also cause \"sensations\" that only the patient feels. As an example, one type of seizure can cause stomach discomfort, fear, or an unpleasant smell. Such subjective feelings are commonly referred to as auras. A person usually experiences the same symptoms with each seizure aura. Sometimes, a seizure aura can occur before a convulsive seizure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Seizure triggers",
"     </span>",
"     &nbsp;&mdash;&nbsp;A minority of people have seizure triggers, such as strong emotions, intense exercise, loud music, or flashing lights. When these triggers are at play, they usually immediately precede the seizure.",
"    </p>",
"    <p>",
"     Although they are more difficult to link to a seizure, other factors can also increase the likelihood that a seizure will happen. As an example, fever, menstrual periods, a lack of sleep, and stress can all increase the risk of seizures in some people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      After a seizure (postictal state)",
"     </span>",
"     &nbsp;&mdash;&nbsp;For many seizure types, you may be unaware during the seizure. When you are told about your behavior during the seizure, you may not believe it because you have no memory of the event.",
"    </p>",
"    <p>",
"     The period following a seizure is called the postictal state. During this time, you may be confused and tired, and you may develop a throbbing headache. This period usually lasts several minutes, although it can last for hours or even days.",
"    </p>",
"    <p>",
"     In some people, the postictal period comes with certain symptoms. For example, you may experience mild to severe weakness in a hand, arm, or leg. Other people have difficulty speaking or experience temporary (partial) vision loss or other types of sensory loss. These can be important clues about the type of seizure and the part of the brain that was affected during the seizure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SEIZURE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     As noted earlier, all seizures are not caused by epilepsy. There are three broad categories of seizure causes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Epileptic seizures &mdash; People with epilepsy have a type of brain dysfunction that intermittently causes episodes of abnormal electrical activity. This can be caused by any type of brain injury, such as trauma, stroke, brain infection, or a brain tumor. In some individuals, epilepsy is an inherited condition. In many cases, the cause of epileptic seizures is not clear.",
"      </li>",
"      <li>",
"       Provoked seizures &mdash; A similar type of abnormal electrical activity in the brain can be caused by certain drugs, alcohol withdrawal, and other imbalances, such as a low blood sugar. Seizures that are caused by problems like these are called \"provoked\" seizures, and they do not usually occur again once the problem is remedied. People with provoked seizures are not said to have epilepsy.",
"      </li>",
"      <li>",
"       Nonepileptic seizures &mdash; Nonepileptic seizures look like seizures, but are not caused by abnormal brain activity. These seizures may be due to fainting spell, a muscle disorder, or a psychological condition.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      SEIZURE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you have a seizure and have never had one before, your healthcare provider will want to get as much information about the seizure as possible. He or she will want to know a detailed description of the episode, if you lost consciousness, stared blankly, or twitched and jerked violently. The more information your healthcare provider has about your seizure, the better able he or she will be to make the right diagnosis.",
"    </p>",
"    <p>",
"     If a witness to the seizure is available and can come to the appointment or be contacted later, this can be very helpful to the physician.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Tests and procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Depending on the circumstances of your seizure, your age, and your individual situation, your healthcare provider may order one or more tests, including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Blood tests may be done to check for problems (such as low or high blood sugar) that may have caused your seizure, and to check for markers in the blood that could point to the type of seizure you had.",
"      </li>",
"      <li>",
"       Lumbar puncture (spinal tap) may be done after a seizure to check for signs of infection. This is usually done in an emergency room, if the individual does not seem to be recovering normally from the seizure, or if the person has a fever or other signs of brain infection.",
"       <br/>",
"       <br/>",
"       During this test, a needle is inserted into the space surrounding the spinal cord and a fluid sample is taken. The sample is checked for bacteria or other signs of signs of infection, such as an abundance of white blood cells.",
"      </li>",
"      <li>",
"       Electroencephalography (EEG) may be done to check for abnormal electrical activity in the brain. During this test, electrode pads are placed on your scalp. The clinician may try to provoke a seizure using flashing lights or by asking you to hyperventilate. Both of these maneuvers may produce abnormalities in your brain waves, which could be helpful in determining your diagnosis.",
"      </li>",
"      <li>",
"       Brain imaging studies, such as MRI or CT scans, may be done to check for tumors, strokes, or other structural problems in the brain. However, these tests are often normal in people with epilepsy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SEIZURE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The appropriate treatment of your seizure will depend upon what type of seizure you had and whether the seizure was caused by epilepsy or another factor.",
"    </p>",
"    <p>",
"     As an example, if your seizure was caused by an infection affecting the brain, treatment of the infection should prevent you from having more seizures. Likewise, if your seizure was caused by a psychological problem, such as anxiety, treatment of the psychological problem should remedy the seizures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Seizure medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have epilepsy or if your seizure was caused by a stroke, tumor, or some type of permanent brain injury, you may to take one or more anti-seizure medications, referred to as antiepileptic drugs (AEDs). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"      \"Initial treatment of epilepsy in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Anti-seizure medications prevent or reduce the number or severity of a person's seizures. Healthcare providers may not recommend starting these drugs until you have had at least two seizures, in part to make sure that the first seizure was not an isolated incident.",
"    </p>",
"    <p>",
"     However, your healthcare provider may recommend an anti-seizure medication after a single seizure if you are at high risk of having a second seizure or if you are at high risk of injury related to the seizure.",
"    </p>",
"    <p>",
"     Starting anti-seizure medication therapy early reduces the risk of another seizure and is generally safe. However, many people dislike taking medications every day, and anti-seizure medications can cause side effects and carry certain risks. Discuss the options for starting an anti-seizure medication with your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Choosing a seizure medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;In selecting a medication, your healthcare provider will consider your seizure type as well as other medical conditions that you might have and medications you may be taking. Finding the right anti-seizure medication may require a number of adjustments in medications and dosages.",
"    </p>",
"    <p>",
"     You will meet regularly with your healthcare provider when you are first trying a new medication, and will start with a low dose and slowly increase it, so that you can find the lowest effective dose.",
"    </p>",
"    <p>",
"     Only about half of the people with a new diagnosis of epilepsy stop having seizures with the first anti-seizure medication [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/27/34229/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]. That means that most people have to try more than one medication before they find one that works well. The best medication is one that offers the most protection from seizures with the fewest possible side effects.",
"    </p>",
"    <p>",
"     The good news is that there are many anti-seizure medications to choose from, so the chances are good that you will find one that works without too many side effects.",
"    </p>",
"    <p>",
"     If you take an anti-seizure medication that causes uncomfortable side effects, such as a skin rash, tell your healthcare provider. In some cases, side effects will go away once you have been taking the medication for a while. In other cases, your healthcare provider may lower your dose or switch you to another medication that is less likely to cause side effects.",
"    </p>",
"    <p>",
"     If a single anti-seizure medication is not effective, your provider may suggest combining two anti-seizure medications. Although this is a sound strategy, combinations of anti-seizure medications are not usually recommended until you have tried at least two anti-seizure medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Generic anti-seizure medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several anti-seizure medications are available as generic formulations, which can help you to save money on the cost of your prescriptions. Most generic medications are as effective as the brand name drug.",
"    </p>",
"    <p>",
"     However, if your clinician has determined that you need a specific brand or form of medication to control your seizures, be sure that your prescription includes the statement \"no interchange\" or \"no substitution\". This lets your pharmacist and insurance company know that the generic drug should not be substituted for the brand name drug.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Each anti-seizure medication can cause side effects, which can affect each person differently. Anyone taking an anti-seizure medication should be aware of some side-effects. These include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       An increased risk of becoming suicidal. If you start to become depressed or have thoughts of harming yourself or others while taking an anti-seizure medication, speak to your healthcare provider right away. (See",
"       <a class=\"local\" href=\"#H19\">",
"        'Psychological and social issues'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       A rare but serious skin disorder called Stevens-Johnson syndrome, which can cause fever and a painful, sometimes blistering, rash that eventually kills the top layer of skin. This side effect is most likely to happen in people taking carbamazepine, oxcarbazepine, phenytoin, and lamotrigine, and it is mostly likely to occur within the first two months of use. If you notice a severe rash while taking an anti-seizure medication, call your healthcare provider right away.",
"      </li>",
"      <li>",
"       A weakening of the bones (osteoporosis). This can occur after long-term use of anti-seizure medications. There are steps you can take to protect and strengthen your bones. If you are concerned about your bone health, or are at risk for osteoporosis, ask your healthcare provider what you can do to keep your bones as healthy as possible. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"        \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"        \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"        \"Pharmacology of antiepileptic drugs\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Seizures that persist despite medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although anti-seizure medications work for many people with seizure disorders, some people continue to have seizures even after trying several medications. For them, other treatments may be an option.",
"    </p>",
"    <p>",
"     For example, surgery to remove the portion of the brain causing the seizures or severing the connection between the two halves of the brain can reduce or eliminate seizures in some people. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41593?source=see_link\">",
"      \"Surgical therapy of epilepsy in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Others may benefit from treatment with an implanted electrical device (vagal nerve stimulator). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"      \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     What's more, several experimental treatments are in development. If you cannot adequately control your seizures with medication, ask your healthcare provider if any other treatment strategies might be appropriate for you.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Increasing your chance for success",
"     </span>",
"     &nbsp;&mdash;&nbsp;The things you do can have a big impact on how well your anti-seizure medication works.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Take your medication exactly as directed, at the right times, and at the right doses. Ask your healthcare provider to write down any special instructions.",
"      </li>",
"      <li>",
"       Ask what side effects you can expect and what to do about them. Even if you develop uncomfortable side effects, don't stop taking your anti-seizure medication without first speaking to your healthcare provider.",
"      </li>",
"      <li>",
"       Be careful not to let your prescription run out. Stopping anti-seizure medication abruptly can put you at risk of seizure.",
"      </li>",
"      <li>",
"       While taking an anti-seizure medication, do not start taking any other medications including over-the-counter medications and herbal supplements without first checking with your healthcare provider. Anti-seizure medication can interact with prescriptions, over-the-counter medications, and herbal supplements, so mixing them can be dangerous.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      LIVING WITH SEIZURES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Seizure calendar",
"     </span>",
"     &nbsp;&mdash;&nbsp;Especially when you first start taking a new medication, it's a good idea to keep a record of seizures as they occur. On a calendar, note any seizures you may have had, and ask those around you to help you keep track. Note, too, any seizure triggers, such as days when you were sleep-deprived, stressed, drank alcohol, or (if you are a woman) had your period.",
"    </p>",
"    <p>",
"     If medication side effects are a problem for you, use the calendar to record them as well. Then bring this calendar with you when you see your healthcare provider. That way, the two of you can work together to understand the factors that contribute to your seizures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Keep appointments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your healthcare provider may ask to see you on a regular basis, especially soon after you start taking anti-seizure medication. These visits are important because they allow your healthcare provider to:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Check how well your medication is working",
"      </li>",
"      <li>",
"       Find out whether you are having troubling side effects",
"      </li>",
"      <li>",
"       Make sure that your kidneys and liver are working properly (anti-seizure medications can sometimes strain these organs)",
"      </li>",
"      <li>",
"       Monitor the level of medication in your blood",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Use the check-up visits to alert your healthcare provider to any problems you may be having, either with your medication or overall health. Having a seizure disorder can be trying, but your healthcare provider can provide insight or solutions if your seizures are presenting obstacles.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who may become pregnant and who require anti-seizure medications should talk to their healthcare provider about their plans for pregnancy.",
"    </p>",
"    <p>",
"     Anti-seizure medications can affect the health of a developing fetus, and they can interfere with the effects of certain birth control methods, so this discussion is important for women regardless of whether or not you want to get pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link\">",
"      \"Management of epilepsy and pregnancy\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link\">",
"      \"Risks associated with epilepsy and pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Psychological and social issues",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having a seizure disorder can be emotionally difficult for a number of reasons.",
"    </p>",
"    <p>",
"     For starters, seizures can be frightening for you and for your friends and loved ones. Depending on their frequency and severity, seizures can also interfere with your ability to drive or even work.",
"    </p>",
"    <p>",
"     Plus, the medications used to control seizures can sometimes cause you to feel depressed or suicidal. If you become depressed or suicidal, or are just having a hard time with your condition, speak to your healthcare provider about your concerns. There may be treatments, services, or strategies that can help you overcome the hurdles you are facing. You may even decide to seek out a support group for people with epilepsy. If nothing else, this will give you a forum in which to discuss issues that affect people like you.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Driving restrictions",
"     </span>",
"     &nbsp;&mdash;&nbsp;States vary widely in driver licensing requirements for people with epilepsy. The most common requirements are that you be free of seizures for a specified period of time and that you submit a doctor's evaluation of your ability to drive safely. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=see_link\">",
"      \"Driving restrictions for patients with seizures and epilepsy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A listing of individual state driving requirements can be found on the Epilepsy Foundation Website at",
"     <a class=\"external\" href=\"file://www.epilepsyfoundation.org/resources/drivingandtravel.cfm\">",
"      www.epilepsyfoundation.org/resources/drivingandtravel.cfm",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Alcohol",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your seizures are well controlled, it may be acceptable to drink small amounts of alcohol (no more than one to two drinks per day). But drinking excessively (three or more drinks per day) increases the risk of seizures, particularly in the hours and days after you drink. What's more, alcohol can interfere with the efficacy of anti-seizure medications.",
"    </p>",
"    <p>",
"     For these reasons, you should limit the amount of alcohol you drink and use caution if you do drink.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     After you have had a seizure, your healthcare provider's first priority will be to determine what type of seizure you had and whether it was caused by a problem unrelated to epilepsy that can be corrected. He or she will likely ask you a series of questions, examine you, and order several tests. If you need to begin treatment with an anti-seizure medication, it's important that you and your healthcare provider come up with a plan together about how you will take your medication and what you will do if you develop side effects or continue to have seizures.",
"    </p>",
"    <p>",
"     Remember, if one medication does not work for you, either because you cannot tolerate the side effects or because you continue to have seizures, your healthcare provider can suggest alternate medications or alternate methods of taking the medication.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287507312\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10425794\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/48/9986?source=see_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/45/40658?source=see_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/0/18434?source=see_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=see_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/5/30802?source=see_link\">",
"      Patient information: Epilepsy and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/42/26274?source=see_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2754?source=see_link\">",
"      Patient information: Myoclonus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/24/1411?source=see_link\">",
"      Patient information: Time to stop driving? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/12/19650?source=see_link\">",
"      Patient information: Brain metastases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/25/19859?source=see_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10425809\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link\">",
"      Clinical neurophysiology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=see_link\">",
"      Driving restrictions for patients with seizures and epilepsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32425?source=see_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22871?source=see_link\">",
"      Magnetic resonance imaging changes related to acute seizure activity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13082?source=see_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=see_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37385?source=see_link\">",
"      Pathophysiology of seizures and epilepsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=see_link\">",
"      Treatment of seizures and epilepsy in the elderly patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40841?source=see_link\">",
"      Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/58/22440?source=see_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link\">",
"      Status epilepticus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41593?source=see_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Epilepsy Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.epilepsyfoundation.org/\">",
"      www.epilepsyfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/epilepsy/detail_epilepsy.htm\">",
"      www.ninds.nih.gov/disorders/epilepsy/detail_epilepsy.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/epilepsy.html\">",
"      www.nlm.nih.gov/medlineplus/epilepsy.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Epilepsy Therapy Development Project",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.epilepsy.com/\">",
"      www.epilepsy.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International League Against Epilepsy and the International Bureau for Epilepsy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.epilepsy.org/\">",
"      www.epilepsy.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/27/34229/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/27/34229?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34229/abstract/1\">",
"      Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34229/abstract/2\">",
"      Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34229/abstract/3\">",
"      Krumholz A, Wiebe S, Gronseth G, et al. Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2007; 69:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34229/abstract/4\">",
"      Krauss GL, Ampaw L, Krumholz A. Individual state driving restrictions for people with epilepsy in the US. Neurology 2001; 57:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34229/abstract/5\">",
"      Jacoby A, Gamble C, Doughty J, et al. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology 2007; 68:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34229/abstract/6\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_27_34229=[""].join("\n");
var outline_f33_27_34229=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           WHAT IS A SEIZURE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SEIZURE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SEIZURE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           SEIZURE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SEIZURE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           LIVING WITH SEIZURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34230="Amiodarone toxicity EM";
var content_f33_27_34230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amiodarone toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph shows an alveolar macrophage with intracytoplasmic lamellar bodies typical of amiodarone toxicity. These phospholipid inclusions account for the foamy appearance of histiocytes and epithelial cells in patients taking amiodarone and can be identified even in patients who lack radiographic or clinical evidence of lung disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34230=[""].join("\n");
var outline_f33_27_34230=null;
var title_f33_27_34231="Microscopic images of secondary breast angiosarcoma";
var content_f33_27_34231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Microscopic images of secondary breast angiosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel reveals a low power view of a photomicrograph of a radiation-associated angiosarcoma. Note the cellular proliferation within the dermis, including pockets of cells, single cells percolating between dermal collagen, and columns of cells that appear to raise the epidermis, forming blisters/nodules (corresponding to the gross appearance of these tumors on the chest wall). Right panel reveals a higher power view of the same tumor showing predominantly spindle cells (and rare epithelioid cells) with large, oval to round vesicular nuclei containing one or more prominent nucleoli and basophilic cytoplasm. These malignant cells form vasoformative channels (arrows)&nbsp;containing erythrocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Alero Inyang and David Lucas.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34231=[""].join("\n");
var outline_f33_27_34231=null;
var title_f33_27_34232="Treatment of early (stage I and II) head and neck cancer: The hypopharynx";
var content_f33_27_34232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Suisui Song, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Joseph K Salama, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34232/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/27/34232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypopharynx lies posterior and inferior to the oropharynx and extends to the esophageal inlet. Over 95 percent of hypopharyngeal cancers are squamous cell carcinomas. Other less common histologies include basaloid squamous carcinomas, spindle cell carcinomas, and minor salivary gland carcinomas.",
"   </p>",
"   <p>",
"    At diagnosis, less than 15 percent of hypopharyngeal cancers are confined to the hypopharynx. Most have spread to the regional lymph nodes (65 percent) or distantly (20 percent). Presenting symptoms can include dysphagia, odynophagia, otalgia, hoarseness,",
"    <span class=\"nowrap\">",
"     dyspnea/stridor,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a painless neck mass.",
"   </p>",
"   <p>",
"    The treatment of early hypopharyngeal cancers is presented here. The treatment of locally advanced hypopharyngeal cancer is discussed separately, as is the management of metastatic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122611127\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopharyngeal cancers account for approximately 6 percent of all head and neck cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/1\">",
"     1",
"    </a>",
"    ]. The worldwide incidence varies from 0.8 to 5 cases per 100,000 persons. Hypopharyngeal cancers are more common in well developed countries compared with less developed areas and are more common in men than women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The median age at diagnosis is 65 years for men and 68 years of age for women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In North America and Europe, smoking and alcohol use are the main risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Tobacco chewing also has been identified as an independent risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/6\">",
"     6",
"    </a>",
"    ]. Other environmental factors associated with hypopharyngeal cancer include iron and vitamin C deficiencies, occupational exposure to asbestos,",
"    <span class=\"nowrap\">",
"     steel/coal",
"    </span>",
"    dusts, iron compound fumes, and exposure to indoor air pollution from solid fuels, such as wood, crop residue, or coal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plummer-Vinson syndrome (the triad of dysphagia, glossitis, and iron deficiency anemia) has been associated with postcricoid hypopharyngeal cancers, especially in women from Scandinavian countries. However, improved nutrition, and iron and vitamin dietary fortification have dramatically reduced the incidence of Plummer-Vinson syndrome in developed countries and thus its role in the etiology of hypopharyngeal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/11\">",
"     11",
"    </a>",
"    ]. Gastric reflux, which leads to chronic irritation of the pharynx, has also been implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12838?source=see_link\">",
"     \"Esophageal webs and rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypopharynx is bordered by the oropharynx superiorly (at the level of the hyoid bone) and the esophageal inlet inferiorly (at the lower end of the cricoid cartilage) (",
"    <a class=\"graphic graphic_figure graphicRef75396 \" href=\"mobipreview.htm?26/56/27525\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The hypopharynx is divided into three anatomic subsites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pyriform sinus is bounded medially and superiorly by the aryepiglottic fold, laterally by the superior edge of the thyroid cartilage, and anterosuperiorly by the pharyngoepiglottic fold. Its apex opens into the esophagus. Cancers arising from the pyriform sinus account for 65 to 85 percent of hypopharyngeal cancers.",
"     </li>",
"     <li>",
"      The posterior pharyngeal wall extends from the level of the vallecula to the level of the cricoarytenoid joints; it is formed by the constrictor muscles covered with a mucosal lining. This area is the origin of approximately 10 to 20 percent of these cancers.",
"     </li>",
"     <li>",
"      The postcricoid space is the dorsal surface of the posterior wall of the larynx, bounded laterally by the pyriform fossa, inferiorly by the inferior edge of the cricoid ring, and superiorly by the apex of the arytenoid cartilage. About 5 to 15 percent of hypopharyngeal tumors arise in the postcricoid space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tumor node metastases (TNM) system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to stage hypopharyngeal cancers (",
"    <a class=\"graphic graphic_table graphicRef55865 \" href=\"mobipreview.htm?36/42/37549\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/13\">",
"     13",
"    </a>",
"    ]. By definition, early stage hypopharyngeal cancers are stage I (primary tumor &le;2 cm, T1N0) or stage II (primary tumor &le;4 cm, T2N0) without clinical evidence of regional lymph node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delineation of tumor size and extent of invasion is critical for selection of appropriate therapy. Hypopharyngeal cancers tend to spread within the mucosa beneath intact epithelium and can involve multiple adjacent mucosal areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routes of primary tumor spread are influenced by hypopharyngeal subsite:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancers of the pyriform sinus can invade the laryngeal paraglottic space anteriorly, the thyroid cartilage laterally, the postcricoid area and cervical esophagus inferiorly, the oropharynx superiorly, and the constrictor muscles and the prevertebral fascia posteriorly.",
"     </li>",
"     <li>",
"      Cancers of the posterior pharyngeal wall extend into the lower oropharynx, while cancers of the postcricoid space can spread superiorly within the hypopharynx and extrapharyngeally. Due to the proximity to the cervical esophagus and prevertebral fascia, fixation to or direct invasion of these organs can occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430870932\">",
"    <span class=\"h2\">",
"     Direct visualization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible fiberoptic endoscopy provides the initial assessment of tumor extent. Typical findings include closure or obliteration of the pyriform fossa, mucosal ulceration, pooling of saliva in the pyriform fossa, edema of the arytenoids, and fixation of the cricoarytenoid joint, true vocal cords, or both.",
"   </p>",
"   <p>",
"    The full extent of hypopharyngeal tumors on the posterior pharyngeal wall can be difficult to appreciate on in-office fiberoptic examination. Therefore, evaluation under anesthesia is desirable. Direct laryngoscopy, performed in the operating room, allows an accurate evaluation of superficial tumor spread. Early pyriform sinus tumors may be very subtle, and examination with a modified Valsalva maneuver (while letting the patient blow against closed lips) may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430870946\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of deep tumor spread (preepiglottic space, paraglottic space, laryngeal framework) cannot be evaluated by endoscopy and thus requires additional radiologic examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contrast-enhanced computed tomography (CT) is typically used as the initial imaging modality to assess local tumor extent and evaluate for pathologic lymphadenopathy. CT is generally the most useful single modality for staging hypopharyngeal cancers, since it can accurately identify gross cartilage invasion. However, CT may not identify minor invasion.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) provides improved soft-tissue imaging and is complementary to CT. MRI can distinguish pharyngeal muscles from the mucosa and lymphoid tissue lining the inner wall of the hypopharynx and has a higher sensitivity for the detection of early cartilage invasion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. However, motion artifacts are particularly frequent at the",
"      <span class=\"nowrap\">",
"       laryngeal/hypopharyngeal",
"      </span>",
"      level, which may limit the utility of MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET/CT)",
"      </span>",
"      scans are more accurate than CT or PET alone for the depiction of malignancy in the head and neck. It can help to evaluate the primary site, identify occult nodal involvement, and detect distant metastasis or synchronous primary tumors that are missed by conventional imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/17-20\">",
"       17-20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a large variation in reported sensitivity and specificity for both CT and MRI in detecting cervical adenopathy, particularly in the clinically negative neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. PET scanning may help to identify pathologically involved lymph nodes that are suspicious on CT or MRI but that do not meet traditional size based criteria for classification as abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/17,23-25\">",
"     17,23-25",
"    </a>",
"    ]. In one series that included 50 patients with previously untreated head and neck squamous cell carcinoma, the positive predictive value and negative predictive value for staging clinically N0 neck by PET-CT were determined to be 58 and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT OF PRIMARY TUMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, radiation therapy (RT) is the treatment of choice for early stage hypopharyngeal cancer. RT results in high rates of laryngeal preservation and can treat both the primary tumor site and all elective nodal stations as a single modality.",
"   </p>",
"   <p>",
"    The choice of RT or surgical resection for a specific patient is based upon a number of factors including patient preference, geographic distance to an RT or surgical center, patient fitness, surgeon and radiation oncologist experience, and technology available to the radiation oncologist and surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122611852\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment for early hypopharyngeal cancer is to achieve locoregional tumor control and long-term survival, while maintaining functional (respiration, swallowing, and speech) organ preservation. Whenever possible, preservation of laryngeal function with a conservative surgical procedure or definitive RT is preferred over total laryngectomy or laryngopharyngectomy. A multidisciplinary approach with input from head and neck surgeons, radiation oncologists, and medical oncologists is recommended.",
"   </p>",
"   <p>",
"    In patients with early-stage hypopharyngeal cancer, overall and disease-specific survival following definitive radiotherapy is comparable to radical surgery (total laryngectomy) or larynx-conserving surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/27\">",
"     27",
"    </a>",
"    ]. Surgery and RT have not been directly compared in randomized trials in patients with early hypopharyngeal cancer.",
"   </p>",
"   <p>",
"    As an example, in one retrospective population-based study, limited to potentially resectable hypopharyngeal cancer patients who received definitive treatment from 1990 and 2000, there was no significant difference in overall or disease-specific survival between those treated with RT and those treated surgically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/28\">",
"     28",
"    </a>",
"    ]. In both groups, the five year disease-specific survival rate for early stage patients was approximately 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/29\">",
"     29",
"    </a>",
"    ]. Five year overall survival is lower for early stage hypopharyngeal cancer compared to early stage cancers arising in other head and neck sites. In a representative series of radiotherapy alone for hypopharyngeal cancer, the actuarial overall five year survival was 52 percent, reflecting the frequency of deaths from other causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local recurrences are the most frequent pattern of progression after definitive radiotherapy. In contrast, distant metastases are more common with surgery. The incidence of neck recurrences is similar with both RT and surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early stage hypopharyngeal cancer, surgery is a treatment option for patients who have disease that is technically resectable for a laryngeal sparing approach. This includes patients with upper pyriform sinus and posterior pharyngeal wall tumors. A wide range of larynx-sparing (conservative) surgical approaches that aim to preserve speech and swallowing have been used in appropriately selected patients with early (T-stage) hypopharyngeal cancer (",
"    <a class=\"graphic graphic_table graphicRef83099 \" href=\"mobipreview.htm?36/0/36875\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/31-37\">",
"     31-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conservative approaches are generally not indicated for early stage patients with transglottic tumor extension, postcricoid invasion, and deep pyriform sinus invasion. Although excellent local control (70 to 90 percent) and functional outcome are reported, most of the series using conservative surgical procedures include the use of induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adjuvant radiotherapy (",
"    <a class=\"graphic graphic_table graphicRef83099 \" href=\"mobipreview.htm?36/0/36875\">",
"     table 2",
"    </a>",
"    ). It is unclear if conservative surgery alone would achieve comparable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total laryngectomy or laryngopharyngectomy, procedures that are typically reserved for T3 and T4 tumors, may also be required for small lesions that involve the pyriform sinus apex or postcricoid region, if surgery is the only modality used.",
"   </p>",
"   <p>",
"    Adjuvant RT or chemoradiotherapy is indicated following surgery for patients who have positive resection margins, lymphovascular or perineural invasion, extranodal extension, or pathologically positive lymph nodes identified after neck dissection. Patients with close margins may also need additional treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Definitive RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive radiation therapy (RT) with a median dose of 70 Gy in 2 Gy fractions to the primary tumor and 46 to 50 Gy to elective nodal regions is feasible for T1 and small T2 hypopharyngeal cancers. Definitive RT has resulted in variable rates of laryngeal preservation, ranging from 41 to 100 percent for T1 tumors and from 41 to 86 percent for T2 tumors (",
"    <a class=\"graphic graphic_table graphicRef51464 \" href=\"mobipreview.htm?37/29/38365\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral elective nodal irradiation including coverage of the retropharyngeal nodes and level V is routinely recommended, due to a high rate of occult lymph node metastasis. Specific considerations needed when irradiating early stage hypopharyngeal cancers include elective coverage of bilateral neck and retropharyngeal nodes, because of the small but real risk of retropharyngeal lymph node failure. Additionally, tumors extending to or arising from the posterior hypopharyngeal wall require a more posterior border splitting the vertebral body when using conventional, non-conformal fields. For those treated with three-dimensional conformal RT or intensity-modulated radiotherapy (IMRT), doses to the spinal cord in this region are typically higher given the proximity of planning volumes. Contemporary RT techniques, as well as the dose and schedule of RT, are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Management of the neck'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute toxicities from RT commonly include mucositis, dysphagia, aspiration, skin hyperpigmentation, and desquamation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/41\">",
"     41",
"    </a>",
"    ]. Chronic dysphagia of various degrees may be seen in the majority of patients after treatment, although not well reported. Serious late toxicities can include chondritis of the larynx, prolonged dysphagia requiring chronic enteral tube feedings, persistent mucosal ulceration, webbing of the pharynx requiring dilatation, and laryngeal edema requiring tracheostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/40\">",
"     40",
"    </a>",
"    ]. Myelitis is an extremely rare complication with properly planned RT, occurring in less than 1 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with an incomplete response to RT and for those with a local recurrence without evidence of distant metastasis, surgery can be considered for salvage therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Surgery following irradiation may be associated with increased frequency of complications compared with initial surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to a high incidence of occult cervical node metastasis (30 to 50 percent) in clinically node-negative hypopharyngeal cancer patients, either elective neck dissection or RT should be a component of initial treatment.",
"   </p>",
"   <p>",
"    The hypopharynx has an extensive lymphatic drainage pattern, which may vary depending upon the specific site of the tumor within the hypopharynx, and hypopharyngeal cancers may spread to multiple lymph node levels. The pyriform sinus drains to levels II to IV (jugulodigastric chain), level V (posterior triangle), and the retropharyngeal lymph nodes (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ). The posterior pharyngeal wall drains to levels II and III and the retropharyngeal lymph nodes. The postcricoid space drains to levels III and V and the paratracheal nodes.",
"   </p>",
"   <p>",
"    Clinically occult microscopic pathologic involvement of multiple lymph node levels can occur in 30 to 50 percent of patients with clinically negative neck nodes. Furthermore, bilateral neck involvement is present in 50 percent of patients with clinically positive neck nodes (",
"    <a class=\"graphic graphic_table graphicRef77954 graphicRef53008 graphicRef65834 \" href=\"mobipreview.htm?29/40/30349\">",
"     table 4A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly involved lymph nodes in the clinical N0 neck are level II (relative frequency of 67 to 75 percent) followed by level III (33 to 75 percent) and level IV (0 to 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. In the clinical N0 neck, retropharyngeal lymph nodes are involved up to 15 percent (0 to 15 percent) of cases and are more common with primary tumors of the posterior pharyngeal wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If surgery is used to treat the primary tumor, bilateral selective neck dissection of levels II, III, and IV should be performed for N0 presentations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who undergo definitive RT to the primary tumor, the neck is treated with RT. The entire bilateral neck, including retropharyngeal and supraclavicular nodes, generally should be part of the treatment volume, even in patients with early tumors and clinically negative neck nodes.",
"   </p>",
"   <p>",
"    The standard dose for clinically uninvolved nodal regions is usually 50 Gy delivered in 2 Gy daily fractions. However, some groups treat smaller fields restricted to the primary tumor and upper cervical lymph nodes for stage I and II pyriform sinus carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/50\">",
"     50",
"    </a>",
"    ]. Either three-dimensional conformal RT or intensity-modulated radiotherapy (IMRT) is routinely used. Given the need to electively irradiate multiple lymph node levels bilaterally, IMRT is preferable as it can be used to minimize radiation dose to the parotid glands. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopharyngeal cancer has a relatively poor prognosis, with estimated five year overall survival rates for stage I and stage II disease of approximately 40 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/48,51\">",
"     48,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor location is associated with prognosis, with pyriform sinus tumors having a higher survival than pharyngeal wall tumors, followed by postcricoid tumors, which have the lowest survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/52\">",
"     52",
"    </a>",
"    ]. Survival also declines with older age, male gender, lower socio-economic status, and black race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Comorbidities have also been shown to correlate with worse outcomes and prognosis, and the hypopharynx subsite compared with other head and neck cancer subsites has increased competing mortality from death resulting from noncancer causes and second malignances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients previously treated for early stage hypopharyngeal primaries are at increased risk for second primary tumors at an annual average rate of 2.1 percent in one series. Such second primary tumors adversely affect overall survival for patients with early hypopharyngeal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/29,50,57\">",
"     29,50,57",
"    </a>",
"    ]. As an example, in one series of 115 patients with stage I and II hypopharyngeal cancer, 65 patients (57 percent) had synchronous or metachronous cancers, and of the 115 patients, 19 died of hypopharyngeal cancer, 10 died of second primary cancers, and 14 died of other causes during the study (median follow-up of 47 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second primary tumors most commonly occur in the upper aerodigestive tract, including the oral cavity, esophagus, and lung. Alcohol consumption strongly increases the risk of developing another malignancy after treatment for laryngeal or hypopharyngeal cancer, and a history of heavy cumulative cigarette smoking increases the risk of developing lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34232/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of hypopharyngeal cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, as approximately 80 to 90 percent of all recurrences occur within this timeframe. Several groups have developed guidelines. As an example, the National Comprehensive Cancer Network (NCCN) recommends history and physical exam every 1 to 3 months year 1, every 2 to 4 months year 2, every 4 to 6 months years 3 to 5, and every 6 to 12 months beyond 5 years. Post treatment baseline imaging of the primary tumor site with CT scan is recommended within 6 months of treatment, with further imaging indicated based on signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms. There is no role for routine",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan following the completion of therapy for early stage hypopharyngeal cancer. &nbsp;",
"   </p>",
"   <p>",
"    Following baseline reassessment, direct visualization on clinical exam is appropriate evaluation of the primary tumor. Continued follow-up beyond five years is generally suggested to assess these patients for late toxicity as well as to evaluate for a second primary malignancy. Because of the higher risk of recurrence and second primary malignancy in those who continue tobacco use, many schedule more frequent surveillance visits for these patients and continue for longer duration (ie, beyond five years). The specific recommendations concerning follow-up and controversies in this area are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irradiated patients are at risk of developing hypothyroidism; thus monitoring of serum thyroid stimulating hormone (TSH) levels is routine in irradiated patients. Dental follow-up should be twice yearly at a minimum for dentate patients who have received radiation. Patients should also have periodic assessment for other treatment-related toxicity (eg, neck fibrosis, carotid stenosis, trismus, and speech and swallowing function).",
"   </p>",
"   <p>",
"    An important aspect of posttreatment follow-up is to evaluate and address any functional problems that might be associated with the diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of the disease. Following irradiation of the hypopharynx, treatment related edema can result in dysphagia and aspiration. Therefore patients with hypopharyngeal tumors often benefit from prospective evaluation and surveillance by speech language pathologists with swallowing exercises and serial evaluation of the efficiency and safety for oral alimentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hypopharynx lies behind and below the oropharynx and extends to the esophageal inlet. It can be divided into three subsites: pyriform sinus, postcricoid area, and posterior pharyngeal wall. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary goals for treatment of early hypopharyngeal cancer (stage I and II) (",
"      <a class=\"graphic graphic_table graphicRef55865 \" href=\"mobipreview.htm?36/42/37549\">",
"       table 1",
"      </a>",
"      ) are to maximize survival outcomes and minimize the functional consequences of the disease and treatment, including voice production, swallowing, and airway protection and patency. For appropriately selected patients, both conservative surgery (minimally invasive and open larynx-sparing surgical approaches) and definitive radiation therapy (RT) have been shown to offer good local tumor control and survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Surgery and RT have not been compared in a randomized trial, and the decision to choose one modality versus the other is patient dependent and should involve a multidisciplinary team.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If surgery is used to treat the primary tumor, we recommend selective neck dissection of levels II, III, and IV for early stage hypopharyngeal cancer (with a clinically negative neck) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For patients who undergo definitive RT, we recommend elective RT to the bilateral neck as the treatment volume, including retropharyngeal and supraclavicular nodes (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients treated with primary surgery, we recommend postoperative RT for those with lymphovascular or perineural invasion, or pathologically positive lymph nodes identified after neck dissection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with positive margins or with extracapsular extension of a positive lymph node benefit from postoperative concurrent chemoradiation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypopharyngeal tumors are associated with one of the highest risks of dysphagia and aspiration both pre- and post-therapy. These patients may benefit from prospective evaluation and surveillance by speech language pathologists with swallowing exercises and serial evaluation of the efficiency and safety for oral alimentation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/1\">",
"      Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/2\">",
"      Curado MP, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 2009; 21:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/3\">",
"      Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48:3282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/4\">",
"      Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008; 122:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/5\">",
"      Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007; 99:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/6\">",
"      Sapkota A, Gajalakshmi V, Jetly DH, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. Int J Cancer 2007; 121:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/7\">",
"      Sapkota A, Gajalakshmi V, Jetly DH, et al. Indoor air pollution from solid fuels and risk of hypopharyngeal/laryngeal and lung cancers: a multicentric case-control study from India. Int J Epidemiol 2008; 37:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/8\">",
"      Marchand JL, Luce D, Leclerc A, et al. Laryngeal and hypopharyngeal cancer and occupational exposure to asbestos and man-made vitreous fibers: results of a case-control study. Am J Ind Med 2000; 37:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/9\">",
"      Shangina O, Brennan P, Szeszenia-Dabrowska N, et al. Occupational exposure and laryngeal and hypopharyngeal cancer risk in central and eastern Europe. Am J Epidemiol 2006; 164:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/10\">",
"      Laforest L, Luce D, Goldberg P, et al. Laryngeal and hypopharyngeal cancers and occupational exposure to formaldehyde and various dusts: a case-control study in France. Occup Environ Med 2000; 57:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/11\">",
"      Wahlberg PC, Andersson KE, Bi&ouml;rklund AT, M&ouml;ller TR. Carcinoma of the hypopharynx: analysis of incidence and survival in Sweden over a 30-year period. Head Neck 1998; 20:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/12\">",
"      Galli J, Cammarota G, Cal&ograve; L, et al. The role of acid and alkaline reflux in laryngeal squamous cell carcinoma. Laryngoscope 2002; 112:1861.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/14\">",
"      Helliwell TR. acp Best Practice No 169. Evidence based pathology: squamous carcinoma of the hypopharynx. J Clin Pathol 2003; 56:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/15\">",
"      Becker M, Burkhardt K, Dulguerov P, Allal A. Imaging of the larynx and hypopharynx. Eur J Radiol 2008; 66:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/16\">",
"      Zb&auml;ren P, Becker M, L&auml;ng H. Pretherapeutic staging of hypopharyngeal carcinoma. Clinical findings, computed tomography, and magnetic resonance imaging compared with histopathologic evaluation. Arch Otolaryngol Head Neck Surg 1997; 123:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/17\">",
"      Rumboldt Z, Gordon L, Gordon L, et al. Imaging in head and neck cancer. Curr Treat Options Oncol 2006; 7:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/18\">",
"      Ng SH, Chan SC, Liao CT, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology 2008; 50:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/19\">",
"      Roh JL, Yeo NK, Kim JS, et al. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 2007; 43:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/20\">",
"      Branstetter BF 4th, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/21\">",
"      de Bondt RB, Nelemans PJ, Hofman PA, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol 2007; 64:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/22\">",
"      Castelijns JA, van den Brekel MW. Imaging of lymphadenopathy in the neck. Eur Radiol 2002; 12:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/23\">",
"      Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/24\">",
"      Ng SH, Yen TC, Chang JT, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006; 24:4371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/25\">",
"      Dulala R, Campian JL, Dubner S, et al. Evaluation of PET imaging in treatment decision making for early stage head and neck squamous cell cancer. J Clin Oncol 2009; 27:r17017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/26\">",
"      Richard C, Prevot N, Timoshenko AP, et al. Preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography imaging in head and neck cancer: does it really improve initial N staging? Acta Otolaryngol 2010; 130:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/27\">",
"      Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2012; 34:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/28\">",
"      Hall SF, Groome PA, Irish J, O'Sullivan B. Radiotherapy or surgery for head and neck squamous cell cancer: establishing the baseline for hypopharyngeal carcinoma? Cancer 2009; 115:5711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/29\">",
"      Hall SF, Groome PA, Irish J, O'Sullivan B. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 2008; 118:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/30\">",
"      Garden AS, Morrison WH, Clayman GL, et al. Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease. Head Neck 1996; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/31\">",
"      Holsinger FC, Motamed M, Garcia D, et al. Resection of selected invasive squamous cell carcinoma of the pyriform sinus by means of the lateral pharyngotomy approach: the partial lateral pharyngectomy. Head Neck 2006; 28:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/32\">",
"      Lydiatt WM, Kraus DH, Cordeiro PG, et al. Posterior pharyngeal carcinoma resection with larynx preservation and radial forearm free flap reconstruction: a preliminary report. Head Neck 1996; 18:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/33\">",
"      Chevalier D, Watelet JB, Darras JA, Piquet JJ. Supraglottic hemilaryngopharyngectomy plus radiation for the treatment of early lateral margin and pyriform sinus carcinoma. Head Neck 1997; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/34\">",
"      Plouin-Gaudon I, Lengel&eacute; B, Desuter G, et al. Conservation laryngeal surgery for selected pyriform sinus cancer. Eur J Surg Oncol 2004; 30:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/35\">",
"      Makeieff M, Mercante G, Jouzdani E, et al. Supraglottic hemipharyngolaryngectomy for the treatment of T1 and T2 carcinomas of laryngeal margin and piriform sinus. Head Neck 2004; 26:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/36\">",
"      Kania R, Hans S, Garcia D, et al. Supracricoid hemilaryngopharyngectomy in patients with invasive squamous cell carcinoma of the pyriform sinus. Part II: Incidence and consequences of local recurrence. Ann Otol Rhinol Laryngol 2005; 114:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/37\">",
"      Laccourreye O, Ishoo E, de Mones E, et al. Supracricoid hemilaryngopharyngectomy in patients with invasive squamous cell carcinoma of the pyriform sinus. Part I: Technique, complications, and long-term functional outcome. Ann Otol Rhinol Laryngol 2005; 114:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/38\">",
"      Shimizu Y, Yoshida T, Kato M, et al. Long-term outcome after endoscopic resection in patients with hypopharyngeal carcinoma invading the subepithelium: a case series. Endoscopy 2009; 41:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/39\">",
"      Martin A, J&auml;ckel MC, Christiansen H, et al. Organ preserving transoral laser microsurgery for cancer of the hypopharynx. Laryngoscope 2008; 118:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/40\">",
"      Rabbani A, Amdur RJ, Mancuso AA, et al. Definitive radiotherapy for T1-T2 squamous cell carcinoma of pyriform sinus. Int J Radiat Oncol Biol Phys 2008; 72:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/41\">",
"      Gupta T, Chopra S, Agarwal JP, et al. Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches. Acta Oncol 2009; 48:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/42\">",
"      Taki S, Homma A, Oridate N, et al. Salvage surgery for local recurrence after chemoradiotherapy or radiotherapy in hypopharyngeal cancer patients. Eur Arch Otorhinolaryngol 2010; 267:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/43\">",
"      Yoshimura R, Kagami Y, Ito Y, et al. Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010; 77:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/44\">",
"      Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified neck dissection. Head Neck Surg 1988; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/45\">",
"      Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990; 160:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/46\">",
"      Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990; 12:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/47\">",
"      McLaughlin MP, Mendenhall WM, Mancuso AA, et al. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. Head Neck 1995; 17:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/48\">",
"      Yoshimoto S, Kawabata K. Retropharyngeal node dissection during total pharyngolaryngectomy for hypopharyngeal cancer. Auris Nasus Larynx 2005; 32:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/49\">",
"      Amatsu M, Mohri M, Kinishi M. Significance of retropharyngeal node dissection at radical surgery for carcinoma of the hypopharynx and cervical esophagus. Laryngoscope 2001; 111:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/50\">",
"      Nakamura K, Shioyama Y, Kawashima M, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65:1045.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/publications/survival/surv_head_neck.pdf (Accessed on March 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/52\">",
"      Farrington WT, Weighill JS, Jones PH. Post-cricoid carcinoma (a ten-year retrospective study). J Laryngol Otol 1986; 100:79.",
"     </a>",
"    </li>",
"    <li>",
"     Chao KS. Practical essentials of intensity modulated radiation therapy, 2nd, Lippincott Williams and Wilkins, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/54\">",
"      Molina MA, Cheung MC, Perez EA, et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer: an examination of 20,915 patients. Cancer 2008; 113:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/55\">",
"      Homma A, Sakashita T, Oridate N, et al. Importance of comorbidity in hypopharyngeal cancer. Head Neck 2010; 32:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/56\">",
"      Rose BS, Jeong JH, Nath SK, et al. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011; 29:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/57\">",
"      Raghavan U, Quraishi S, Bradley PJ. Multiple primary tumors in patients diagnosed with hypopharyngeal cancer. Otolaryngol Head Neck Surg 2003; 128:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34232/abstract/58\">",
"      Dikshit RP, Boffetta P, Bouchardy C, et al. Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma. Cancer 2005; 103:2326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3397 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34232=[""].join("\n");
var outline_f33_27_34232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H122611127\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H430870932\">",
"      Direct visualization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H430870946\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT OF PRIMARY TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122611852\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Definitive RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT OF THE NECK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3397|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27525\" title=\"figure 1\">",
"      Anatomy of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3397|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/42/37549\" title=\"table 1\">",
"      TNM stage hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/0/36875\" title=\"table 2\">",
"      Conservative surgeries approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/29/38365\" title=\"table 3\">",
"      Outcomes RT series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/23/15739\" title=\"table 4A\">",
"      Percent nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/1/21532\" title=\"table 4B\">",
"      Distrib nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/13/19675\" title=\"table 4C\">",
"      Distrib RP nodal metastases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12838?source=related_link\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34233="Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age";
var content_f33_27_34233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34233/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/27/34233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood and adolescent immunizations are one of the most effective means of preventing serious illness. Diphtheria, tetanus, and pertussis immunization in children and adolescents 7 through 18 years of age will be discussed here. Diphtheria, tetanus, and pertussis immunization in children zero through six years of age and other childhood immunizations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria is an acute respiratory or cutaneous illness caused by",
"    <em>",
"     Corynebacterium diphtheriae",
"    </em>",
"    . Respiratory diphtheria has a case fatality rate of 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=see_link\">",
"     \"Diagnosis and treatment of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tetanus is a nervous system disorder characterized by muscle spasms. It is caused by",
"    <em>",
"     Clostridium tetani",
"    </em>",
"    , a toxin-producing anaerobe. Mortality is increased among unvaccinated persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pertussis, or \"whooping cough\", is an acute respiratory illness caused by",
"    <em>",
"     Bordetella pertussis",
"    </em>",
"    . The case fatality rate for pertussis is approximately 0.2 percent; mortality is increased among infants younger than three months of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16248?source=see_link\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines for diphtheria, tetanus, and pertussis were introduced into the routine childhood immunization schedule in the United States during the 1940s, with dramatic effects on disease incidence (",
"    <a class=\"graphic graphic_figure graphicRef72244 \" href=\"mobipreview.htm?23/7/23679\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53397 \" href=\"mobipreview.htm?2/5/2143\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62288 \" href=\"mobipreview.htm?28/32/29199\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vaccine preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines for children &ge;7 years, adolescents, and adults contain less diphtheria toxoid and pertussis antigen (if they contain pertussis antigens) than the vaccines that are used for children &lt;7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Vaccines for children &ge;7 years also may contain less tetanus toxoid (",
"    <a class=\"graphic graphic_table graphicRef73107 \" href=\"mobipreview.htm?33/15/34045\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diphtheria-, tetanus-,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis-containing vaccines for children aged 7 through 18 years include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tdap &ndash; Tdap contains tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. The pertussis antigens that are included vary depending upon the vaccine product (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"mobipreview.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      ). Two Tdap vaccines are approved by the United States Food and Drug Administration (FDA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      BOOSTRIX, for use in individuals &ge;10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/6\">",
"       6",
"      </a>",
"      ]. The tip and rubber plunger of the needleless syringe contain latex; the single-dose vial, however, does not contain latex.",
"     </li>",
"     <li>",
"      Adacel, for use in individuals 11 through 64 years of age; Adacel is available in single-dose vials that are latex free [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The Advisory Committee on Immunization Practices (ACIP) recommends off-label use of Tdap for children between 7 and 10 years of age who are not fully vaccinated against pertussis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       '7 to 10 years'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Catch-up schedule'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Tdap vaccines do not contain thimerosal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Care must be taken to distinguish Tdap from the diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine (DTaP) used in children &lt;7 years (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"mobipreview.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link&amp;anchor=H3#H3\">",
"       \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Vaccines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Td &ndash; Td contains tetanus toxoid and reduced diphtheria toxoid. Care must be taken to distinguish Td from the diphtheria toxoid-tetanus toxoid vaccine (DT) used in children &lt;7 years in whom it is desirable to avoid the pertussis vaccine (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"mobipreview.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      ). Some preparations of Td may contain latex and trace amounts of thimerosal (ie, &lt;0.01 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Immunization with conjugate vaccines that contain diphtheria toxoid (eg, the quadrivalent meningococcal conjugate vaccine) is not a substitute for diphtheria toxoid immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single-antigen tetanus toxoid &ndash; The single-antigen tetanus toxoid (TT) preparation is approved for use as a booster dose in children &ge;7 years or adults when combined-antigen preparations are not indicated (eg, a documented severe allergic reaction to diphtheria toxoid). TT preparations may contain latex",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      trace amounts (&le;0.01 percent) of thimerosal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of vaccine depends upon the age of the child or adolescent and whether he or she has received a dose of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     7 to 10 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acellular pertussis-containing vaccines are not licensed for children 7 to 10 years of age. Children in this age group do not require diphtheria, tetanus, or pertussis immunization if they are fully vaccinated (",
"    <a class=\"graphic graphic_figure graphicRef58209 \" href=\"mobipreview.htm?26/56/27523\">",
"     figure 4",
"    </a>",
"    ). Full vaccination is defined by five doses of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine [DTaP] or four doses of DTaP if the fourth dose was administered on or after the fourth birthday.",
"   </p>",
"   <p>",
"    In 2011, in response to an increase in pertussis cases in the United States, the ACIP and the American Academy of Pediatrics (AAP) published updated recommendations for the use of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. The updated guidelines include a recommendation for off-label use of Tdap in children aged 7 through 10 years who are not fully vaccinated against pertussis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. Tdap is preferred to DTaP for this age group because it causes fewer adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children age 7 to 10 years who are not fully vaccinated against pertussis and who have no contraindications to pertussis vaccine should receive a single dose of Tdap to provide protection against pertussis. Additional doses of tetanus toxoid-reduced diphtheria toxoid (Td) should be administered as necessary according to the catch-up schedule (",
"    <a class=\"graphic graphic_table graphicRef72079 \" href=\"mobipreview.htm?19/52/20302\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Contraindications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Catch-up schedule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children 7 through 10 years of age who have never been vaccinated against tetanus, diphtheria, or pertussis or whose vaccination status is unknown should receive a series of three tetanus- and diphtheria-containing vaccines (",
"    <a class=\"graphic graphic_table graphicRef72079 \" href=\"mobipreview.htm?19/52/20302\">",
"     table 2",
"    </a>",
"    ). The preferred schedule is a single dose of Tdap (if there are no contraindications to pertussis vaccine) followed by a dose of Td &ge;4 weeks later and a second dose of Td 6 to 12 months after the first. Tdap can be substituted for either of the Td doses if Tdap is not administered as the first dose in the series. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Contraindications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Catch-up schedule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children who receive Tdap between ages 7 and 10 years should be considered up-to-date for school entry requirements. They should not be revaccinated with Tdap during adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     10 through 18 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP, the AAP Committee on Infectious Diseases, the American Academy of Family Physicians (AAFP), and the Society for Adolescent Medicine recommend a single booster dose of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) for adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Tdap may be substituted for any indicated dose of Td in a child &ge;10 years of age (for BOOSTRIX) and &ge;11 years of age (for Adacel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dose and route",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of diphtheria toxoid, tetanus toxoid, and pertussis vaccines is 0.5 mL. The vaccine is administered intramuscularly. The deltoid muscle is the preferred site for administration, but the anterolateral thigh can also be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Storage and handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccines should be stored continuously at 35&ordm; to 46&ordm;F (2&ordm; to 8&ordm;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/18\">",
"     18",
"    </a>",
"    ]. During transport, the vaccine may be out of refrigeration for as long as four days, but it should be refrigerated immediately upon arrival. Freezing reduces the potency of the tetanus component; vaccine exposed to freezing temperature should not be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Efficacy and effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and effectiveness of diphtheria, tetanus, and pertussis immunization vary depending upon the definition used for efficacy (ie, antibody levels correlated with protection or protection from disease) and the number of doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117307230\">",
"    <span class=\"h3\">",
"     Td",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a series of three appropriately spaced doses of tetanus toxoid-reduced diphtheria toxoid (Td) vaccines, approximately 95 percent of adolescents and adults achieve levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    correlated with protection (&gt;0.1 international unit of",
"    <span class=\"nowrap\">",
"     antitoxin/mL),",
"    </span>",
"    and virtually all adolescents and adults achieve levels of tetanus antitoxin correlated with protection (&gt;0.1 international unit of",
"    <span class=\"nowrap\">",
"     antitoxin/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Levels of antibody diminish with time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/19\">",
"     19",
"    </a>",
"    ]. Booster doses of tetanus toxoid, reduced diphtheria toxoid are necessary every 10 years throughout life. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Routine schedule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <br/>",
"    The estimated efficacy of diphtheria toxoid in the prevention of diphtheria disease is 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical efficacy of tetanus toxoid has not been studied in vaccine trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of immunization with diphtheria-tetanus toxoid is demonstrated by the decline of these diseases in the United States after the immunizations were added to the routine immunization schedule in the 1940s (",
"    <a class=\"graphic graphic_figure graphicRef72244 \" href=\"mobipreview.htm?23/7/23679\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53397 \" href=\"mobipreview.htm?2/5/2143\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1,2,20\">",
"     1,2,20",
"    </a>",
"    ]. Most cases of diphtheria and tetanus in the United States occur in inadequately immunized persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117307237\">",
"    <span class=\"h3\">",
"     Tdap",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized controlled trials, virtually all adolescent and adult recipients of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) developed antibody levels of tetanus and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    correlated with protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5,21,22\">",
"     5,21,22",
"    </a>",
"    ]. Booster response rates to these antigens were achieved in &ge;90 percent.",
"   </p>",
"   <p>",
"    In a randomized trial, the efficacy of Tdap in preventing laboratory-confirmed pertussis in adolescents and adults was 92 percent (95% CI 32-99 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .) In an observational study, the effectiveness of Tdap in preventing laboratory-confirmed pertussis in adolescents was 85 percent (95% CI 83-87.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/24\">",
"     24",
"    </a>",
"    ]. In a 2007 outbreak, Tdap was 66 percent effective in preventing confirmed or probable pertussis among vaccinated students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in more recent national surveillance and a state-wide outbreak, the incidence of pertussis was increased among 13- and 14-year-olds, despite recent administration of Tdap (",
"    <a class=\"graphic graphic_figure graphicRef86449 \" href=\"mobipreview.htm?6/61/7135\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/26\">",
"     26",
"    </a>",
"    ]. Possible explanations for the increased incidence in this age group and in 8- to 12-year-olds, include early waning of immunity after Tdap or the switch from whole-cell to acellular pertussis-containing vaccines for the primary vaccine series in the late 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. During the 2009-2011 outbreak in Queensland, Australia, the risk of pertussis in a cohort of children born in 1998 was increased among those who completed their primary series with acellular versus whole-cell pertussis vaccine (373 versus 113 cases per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/30\">",
"     30",
"    </a>",
"    ]. Similarly, among fully vaccinated individuals (age 8 to 20 years) who developed pertussis during a state-wide outbreak, the risk of pertussis was increased among individuals who received only acellular pertussis vaccines compared with those who received at least one dose of whole-cell pertussis vaccine (786 versus 92 cases per 100,000 [RR 8.6]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/29\">",
"     29",
"    </a>",
"    ]. Additional studies of Tdap effectiveness and the duration of protection in adolescents fully vaccinated with acellular pertussis-containing vaccines are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP), American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) recommend a single booster dose of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) (0.5 mL IM) for adolescents age 11 through 18 years (",
"    <a class=\"graphic graphic_figure graphicRef58209 \" href=\"mobipreview.htm?26/56/27523\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"     15",
"    </a>",
"    ]. Thereafter, adolescents and adults should receive a booster dose of tetanus toxoid-reduced diphtheria toxoid (Td) every 10 years.",
"   </p>",
"   <p>",
"    Indications for diphtheria, tetanus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis immunization in unimmunized or underimmunized individuals (including those who have not yet received a dose of Tdap) include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5,8,31\">",
"     4,5,8,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wound management or tetanus disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diphtheria disease or close contact of individual with diphtheria disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=see_link\">",
"       \"Diagnosis and treatment of diphtheria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased risk of pertussis (living in an area with a high rate of endemic pertussis or during an outbreak), attending a school or workplace with a high rate of endemic pertussis or during an outbreak, having close direct contact with a case of pertussis (eg, family, residential facility, school-related activity) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25833?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Vaccination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased risk of complications from pertussis (eg, neurologic, muscular, or cardiac disorder; airway or pulmonary disorder)",
"     </li>",
"     <li>",
"      Anticipated close contact with an infant younger than 12 months of age (eg, household member, out-of-home caregiver)",
"     </li>",
"     <li>",
"      Healthcare workers who have direct patient contact in hospitals or clinics",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VACCINE SCHEDULE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Routine schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, children generally receive five doses of diphtheria, tetanus, and pertussis vaccine before seven years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link&amp;anchor=H11#H11\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Vaccine schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single dose of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccine is recommended for individuals between 11 and 18 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"     15",
"    </a>",
"    ]. Age 11 to 12 years is the preferred age for this dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Children who received Tdap between ages 7 and 10 years as part of a catch-up series should not be revaccinated with Tdap during adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     '7 to 10 years'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Immunization with Tdap is encouraged for adolescents who received a tetanus toxoid-reduced diphtheria toxoid (Td) booster at age 11 to 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This recommendation is made to protect adolescents against pertussis and to prevent the spread of pertussis disease to infants, young children, and others at risk for pertussis complications. It is particularly important for adolescents who will have, or anticipate having, close contact with an infant younger than 12 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2011, the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) published recommendations removing the minimum interval between a tetanus- or diphtheria-toxoid-containing vaccine and Tdap when Tdap is otherwise indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. However, the minimum intervals in the catch-up schedule should continue to be followed (",
"    <a class=\"graphic graphic_table graphicRef72079 \" href=\"mobipreview.htm?19/52/20302\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After the adolescent booster dose, individuals should receive Td every 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"     15",
"    </a>",
"    ]. Adults older than 19 years who did not receive a dose of Tdap during adolescence should substitute Tdap for one booster dose of Td. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Administration with other vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) or tetanus toxoid-reduced diphtheria toxoid (Td) may be administered at the same visit as other recommended vaccines (eg, meningococcal conjugate vaccine, human papillomavirus, influenza) (",
"    <a class=\"graphic graphic_figure graphicRef58209 \" href=\"mobipreview.htm?26/56/27523\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5,16,33,34\">",
"     5,16,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If Tdap and meningococcal conjugate vaccine are not administered at the same visit, they can be administered in any sequence, with no minimum interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Catch-up schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catch-up schedule for children &ge;7 years and adolescents with lapsed or incomplete diphtheria, tetanus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis immunization is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef72079 \" href=\"mobipreview.htm?19/52/20302\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Incomplete pertussis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with incomplete pertussis immunization (ie, because there was a precaution to administration of pertussis vaccine during childhood) generally should receive tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) for their adolescent booster dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Precautions to administration of diphtheria toxoid-tetanus toxoid-acellular pertussis (DTaP) vaccine to children &lt;7 years are not necessarily precautions to administration of Tdap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link&amp;anchor=H22#H22\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Precautions'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Not contraindications or precautions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Incomplete records",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing can be performed in children and adolescents for whom documentation of immunization against diphtheria and tetanus is incomplete despite an adequate history of immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"     5",
"    </a>",
"    ]. If tetanus and diphtheria antibody concentrations are &ge;0.1 international",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    previous immunization can be presumed and the adolescent booster dose of Tdap administered as indicated. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Routine schedule'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When tetanus prophylaxis is necessary for wound management (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"     table 3",
"    </a>",
"    ), tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) may be substituted for tetanus toxoid-reduced diphtheria toxoid (Td) if Tdap is available, the child is older than 10 years (for BOOSTRIX) or 11 years (for Adacel), and Tdap and has not been administered previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The meningococcal conjugate vaccine should be administered at the same visit if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Administration with other vaccines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Tdap not available",
"    </span>",
"    &nbsp;&mdash;&nbsp;If tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) is indicated but not available, and the last dose of tetanus toxoid-containing vaccine was administered &ge;10 years previously, tetanus toxoid-reduced diphtheria toxoid (Td) should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"     5",
"    </a>",
"    ]. If the last dose of tetanus toxoid-containing vaccine was administered &lt;10 years previously, immunization can be deferred pending availability of Tdap if the patient is likely to return for follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     History of diphtheria, tetanus, or pertussis disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural infection with diphtheria or tetanus disease does not induce immunity. Individuals with diphtheria or tetanus disease should receive tetanus toxoid-reduced diphtheria toxoid during their convalescence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis and treatment of diphtheria\", section on 'Follow up'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link&amp;anchor=H27#H27\">",
"     \"Tetanus\", section on 'Active immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Well-documented pertussis disease (eg, positive culture or epidemiologic linkage to a culture-proven case) confers short-term immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, the duration of protection is unknown. Adolescents with a history of pertussis infection should receive tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Vaccine mix-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadvertent administration of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) instead of tetanus toxoid-reduced diphtheria toxoid (Td) to a child aged 7 to 10 years should be counted as the adolescent Tdap booster [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"       5",
"      </a>",
"      ]. The child should receive Td 10 years after the inadvertent dose. Children who receive Tdap between ages 7 and 10 years should be considered up-to-date for school entry requirements. They should not be revaccinated with Tdap during adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadvertent administration of diphtheria toxoid-tetanus toxoid-acellular pertussis (DTaP) vaccine (rather than Td or Tdap) to a child older than seven years should count as the adolescent Tdap booster [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"       5",
"      </a>",
"      ]. The child should receive Td 10 years after the inadvertent dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine administration errors should be reported to the Vaccine Adverse Event Reporting System (",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     VAERS",
"    </a>",
"    ) (telephone number 1-800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications, precautions, and conditions that are neither contraindications nor precautions (and therefore should not be used to defer immunization) for diphtheria toxoid-, tetanus toxoid-,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acellular pertussis-containing vaccines are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef79169 \" href=\"mobipreview.htm?16/48/17165\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute contraindications to diphtheria, tetanus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis immunizations include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5,35\">",
"     4,5,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylactic reaction to the diphtheria, tetanus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pertussis vaccine or vaccine constituent (contraindication to subsequent doses of all components)",
"     </li>",
"     <li>",
"      Encephalopathy within seven days of the administration of a previous dose of the vaccine without another identifiable cause (this is a contraindication to tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap); tetanus toxoid-reduced diphtheria toxoid (Td) should be administered) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Vaccine preparations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Some Tdap and Td vaccines contain latex and are contraindicated in patients with anaphylactic reaction to latex",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precautions are conditions that might increase the risk for a serious reaction to immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/18\">",
"     18",
"    </a>",
"    ]. Precautions to immunization with tetanus toxoid-reduced diphtheria toxoid (Td) or tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4-6,18\">",
"     4-6,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate or severe illness with or without fever; immunization may be administered upon recovery",
"     </li>",
"     <li>",
"      History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria-toxoid containing vaccines (including quadrivalent meningococcal conjugate vaccine)",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome (GBS) within six weeks after previous dose of tetanus toxoid- or diphtheria toxoid-containing vaccine (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Adverse reactions'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Unstable neurologic disorder (for Tdap only)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Past cutaneous reactions involving skin necrosis (Arthus-type reaction)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deferral of tetanus-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diphtheria toxoid-containing vaccine (including quadrivalent meningococcal conjugate vaccine) for a minimum of 10 years after the last dose may be warranted for patients with a history of a past cutaneous reaction involving skin hemorrhage or necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This type of local reaction may represent an Arthus reaction, although the mechanism has not been proven. The history of the reaction should be reviewed to verify the signs and symptoms; consultation with an allergist or immunologist may be warranted.",
"   </p>",
"   <p>",
"    The Arthus reaction is a laboratory model of a type III or immune complex mediated hypersensitivity reaction. Arthus reactions can be induced in animals that have been previously immunized to form IgG against an antigen. If the antigen is later injected into the skin, immune complexes may form locally, with symptoms beginning several hours later. These immune complexes cause activation of mast cells, neutrophil recruitment, and occlusion of capillaries with platelets. Local inflammation with hemorrhage at the site and sometimes superficial skin necrosis can ensue. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Adverse reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If such a reaction occurred after immunization with diphtheria toxoid but not tetanus toxoid (eg, after immunization with meningococcal conjugate vaccine, which contains diphtheria toxoid), and it has been more than 10 years since the last dose of tetanus toxoid-containing vaccine, tetanus toxoid (TT) may be administered. Alternatively, serology may be performed to determine whether the adolescent has levels of tetanus antitoxin correlated with protection (&ge;0.1 international",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Not contraindications or precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions are neither contraindications nor precautions for tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) or tetanus toxoid-reduced diphtheria toxoid (Td); several of the conditions are precautions to the administration of diphtheria toxoid-tetanus toxoid-acellular pertussis (DTaP) or diphtheria toxoid-tetanus toxoid-whole cell pertussis (DTwP) in children &lt;7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5,18,36\">",
"     4,5,18,36",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link&amp;anchor=H22#H22\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Precautions'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature &ge;105&ordm;F (40.5&ordm;C) within 48 hours after DTaP or DTwP (not attributable to another cause)",
"     </li>",
"     <li>",
"      Hypotonic hyporesponsive episode within 48 hours after DTaP or DTwP",
"     </li>",
"     <li>",
"      Convulsions with or without fever within three days of DTaP or DTwP",
"     </li>",
"     <li>",
"      History of extensive limb swelling after DTaP or DTwP that is not an Arthus-type reaction",
"     </li>",
"     <li>",
"      Stable or resolved neurologic disorder (eg, well-controlled seizures, developmental delay, cerebral palsy)",
"     </li>",
"     <li>",
"      History of contact latex allergy",
"     </li>",
"     <li>",
"      Immunosuppression, including HIV infection",
"     </li>",
"     <li>",
"      Mild acute illness with or without fever",
"     </li>",
"     <li>",
"      Breast-feeding",
"     </li>",
"     <li>",
"      Use of antimicrobials",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117306647\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) was confirmed in postmarketing surveillance of more than 13,000 adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/37\">",
"     37",
"    </a>",
"    ]. There was no increased risk of medically attended neurologic, hematologic, or allergic reactions on days 0 to 29 after Tdap vaccination compared with days 30 to 59 after vaccination, nor was there an increased risk of new-onset chronic illness in recipients of Tdap compared with historical recipients of tetanus toxoid-reduced diphtheria toxoid (Td).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to the tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccine include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local reactions &ndash; Mild local reactions (eg, pain, redness, swelling) may occur after immunization with tetanus toxoid-reduced diphtheria (Td) or Tdap. In prelicensure studies, mild local reactions occurred with similar frequency: pain (approximately 70 to 80 percent), erythema (approximately 20 percent), and swelling (approximately 20 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"       5",
"      </a>",
"      ]. Severe local reactions are less frequent (&le;6 percent for either Td or Tdap).",
"     </li>",
"     <li>",
"      Systemic reactions &ndash; Systemic reactions also may occur after immunization with Td or Tdap: fever (3 to 14 percent), headache (approximately 40 percent), fatigue (approximately 30 to 35 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Fever &gt;102.2&ordm;F, severe headache, and severe fatigue occur in less than 4 percent.",
"     </li>",
"     <li>",
"      Syncope &ndash; Syncope following immunization appears to be more common among adolescents and young adults than other age groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5,18,38-40\">",
"       5,18,38-40",
"      </a>",
"      ]. The Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) suggest that patients be observed for 15 minutes after immunization and that personnel take appropriate measures to prevent injuries if weakness, dizziness, or loss of consciousness occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/18,40,41\">",
"       18,40,41",
"      </a>",
"      ]. Having the recipient sit or lie down for 15 minutes after vaccination may prevent syncopal episodes and secondary injuries. If syncope occurs, patients should be observed until symptoms resolve.",
"     </li>",
"     <li>",
"      Local reactions with skin hemorrhage and necrosis &ndash; Arthus-type reactions can occur after vaccines containing tetanus or diphtheria toxoid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"       5",
"      </a>",
"      ]. They typically occur 4 to 12 hours after vaccination and are characterized by severe pain, swelling, induration, edema, hemorrhage, and occasionally necrosis at the site of the injection. They generally resolve without sequelae. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Past cutaneous reactions involving skin necrosis (Arthus-type reaction)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome &ndash; There have been rare case reports of Guillain-Barr&eacute; syndrome (GBS) following tetanus toxoid-containing vaccines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5,42-44\">",
"       5,42-44",
"      </a>",
"      ]. However, an association between GBS and tetanus vaccination has not been demonstrated during active surveillance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5,45,46\">",
"       5,45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Vaccination'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      GBS also been reported after meningococcal conjugate vaccine, which contains diphtheria toxoid. The possible association between meningococcal conjugate vaccine and GBS is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H9#H9\">",
"       \"Meningococcal vaccines\", section on 'Possible association with Guillain-Barr&eacute; syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources related to immunization in children 7 through 18 years of age include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/\">",
"       The Centers for Disease Control and Prevention",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www2.aap.org/healthtopics/immunizations.cfm\">",
"       The American Academy of Pediatrics",
"      </a>",
"     </li>",
"     <li>",
"      Vaccine information statement for tetanus toxoid-reduced diphtheria toxoid (Td) and tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/vis/default.htm\">",
"       www.cdc.gov/vaccines/pubs/vis/default.htm#tdtdap",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.immunize.org/\">",
"       Immunization Action Coalition",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/38/36450?source=see_link\">",
"       \"Patient information: Whooping cough (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/34/31266?source=see_link\">",
"       \"Patient information: Tetanus (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=see_link\">",
"       \"Patient information: Tdap vaccine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In accord with the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP), we recommend a single booster dose of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccine for adolescents 11 through 18 years of age (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional indications for tetanus-, reduced diphtheria-,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acellular pertussis-containing vaccine in unimmunized or underimmunized individuals (including those who have not yet received a dose of Tdap) include wound management or tetanus disease; diphtheria disease or close contact of individual with diphtheria; increased risk of pertussis or complications from pertussis; and anticipated close contact with an infant younger than 12 months of age. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred age for Tdap is 11 to 12 years. Thereafter, individuals should receive a booster dose of tetanus toxoid-reduced diphtheria toxoid (Td) every 10 years. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Routine schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The catch-up schedule for children &ge;7 years and adolescents with lapsed or incomplete diphtheria, tetanus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pertussis immunization is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef72079 \" href=\"mobipreview.htm?19/52/20302\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Catch-up schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absolute contraindications, precautions, and conditions that are neither contraindications nor precautions to administration of Tdap and Td are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef79169 \" href=\"mobipreview.htm?16/48/17165\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild local (pain, redness, swelling) and systemic (fever, headache, fatigue) reactions are the most common adverse events after Tdap or Td. More serious reactions include syncope and Arthus-type reactions. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink book, 12th ed. Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Tetanus. In:  Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. Washington DC: Public Health Foundation, 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Pertussis. In:  Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. Washington DC: Public Health Foundation, 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/5\">",
"      Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     BOOSTRIX (tetanus toxoid, reduced diptheria toxoid and acellular pertussis vaccine, adsorbed) prescribing information, 2011. file://us.gsk.com/products/assets/us_boostrix.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     Adacel (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) prescribing information, 2010. https://www.vaccineshoppe.com/image.cfm?image_type=product_pdf&amp;pi=400-10 (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Thimerosal in vaccines. www.fda.gov/CBER/vaccine/thimerosal.htm#t1 (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diphtheria. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/11\">",
"      Centers for Disease Control and Prevention, American Academy of Pediatrics Committee on Infectious Diseases. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Pediatrics 2011; 128:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/12\">",
"      Langley JM, Predy G, Guasparini R, et al. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 2007; 25:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/13\">",
"      Meyer CU, Habermehl P, Knuf M, et al. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin 2008; 4:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/14\">",
"      Scheifele DW, Halperin SA, Ochnio JJ, et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005; 24:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/15\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/16\">",
"      Cassidy WM, Jones G, Williams K, et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005; 36:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/17\">",
"      Middleman AB, Bruner A. Tetanus, diphtheria, and acellular pertussis vaccine: a position statement of the Society for Adolescent Medicine. J Adolesc Health 2009; 45:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/18\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/19\">",
"      Sin MA, Zenke R, R&ouml;nckendorf R, et al. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Pediatr Infect Dis J 2009; 28:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/20\">",
"      Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/21\">",
"      Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr Infect Dis J 2005; 24:S117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/22\">",
"      Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/23\">",
"      Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/24\">",
"      Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009; 28:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/25\">",
"      Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010; 51:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis epidemic--Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/27\">",
"      Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/28\">",
"      Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/29\">",
"      Witt MA, Arias L, Katz PH, et al. Reduced Risk of Pertussis Among Persons Ever Vaccinated With Whole Cell Pertussis Vaccine Compared to Recipients of Acellular Pertussis Vaccines in a Large US Cohort. Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/30\">",
"      Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged &lt;12 months --- Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/32\">",
"      de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010; 50:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/33\">",
"      Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010; 29:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/34\">",
"      Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010; 125:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008; 57:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/36\">",
"      Zepp F, Knuf M, Habermehl P, et al. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 2006; 149:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/37\">",
"      Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010; 29:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/38\">",
"      Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med 1997; 151:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/39\">",
"      Woo EJ, Ball R, Braun MM. Fatal syncope-related fall after immunization. Arch Pediatr Adolesc Med 2005; 159:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Tetanus (lockjaw). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.707.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/42\">",
"      Pollard JD, Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci 1978; 37:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/43\">",
"      Bakshi R, Graves MC. Guillain-Barr&eacute; syndrome after combined tetanus-diphtheria toxoid vaccination. J Neurol Sci 1997; 147:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/44\">",
"      Newton N Jr, Janati A. Guillain-Barr&eacute; syndrome after vaccination with purified tetanus toxoid. South Med J 1987; 80:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/45\">",
"      Tuttle J, Chen RT, Rantala H, et al. The risk of Guillain-Barr&eacute; syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health 1997; 87:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34233/abstract/46\">",
"      Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2838 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34233=[""].join("\n");
var outline_f33_27_34233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vaccine preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - 7 to 10 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - 10 through 18 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dose and route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Storage and handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy and effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H117307230\">",
"      - Td",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H117307237\">",
"      - Tdap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VACCINE SCHEDULE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Routine schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Administration with other vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Catch-up schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Incomplete pertussis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Incomplete records",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Wound management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Tdap not available",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - History of diphtheria, tetanus, or pertussis disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Vaccine mix-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Past cutaneous reactions involving skin necrosis (Arthus-type reaction)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Not contraindications or precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117306647\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2838|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/7/23679\" title=\"figure 1\">",
"      Diphtheria epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/5/2143\" title=\"figure 2\">",
"      Tetanus epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/32/29199\" title=\"figure 3\">",
"      Pertussis epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27523\" title=\"figure 4\">",
"      Childhood immunization schedule 7 to 18 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/61/7135\" title=\"figure 5\">",
"      US pertussis cases by age 2012",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/15/34045\" title=\"table 1\">",
"      DTaP DT TdaP Td vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/52/20302\" title=\"table 2\">",
"      Catch-up immunization schedule for children 7 to 18 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 3\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/48/17165\" title=\"table 4\">",
"      Tdap Td contraindications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=related_link\">",
"      Diagnosis and treatment of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=related_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/34/31266?source=related_link\">",
"      Patient information: Tetanus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34234="Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation";
var content_f33_27_34234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Evelyn Regar, MD, PhD, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Neil J Weissman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     J Brent Muhlestein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/27/34234/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/27/34234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4683151\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive, x-ray coronary angiography using contrast media at the time of cardiac catheterization is the preferred diagnostic test when information regarding the extent and severity of atherosclerotic narrowing in the coronary circulation is needed. Decisions regarding the need for revascularization are based on information obtained from this procedure, as well as other clinical and non-invasive data. However, coronary angiography is subject to observer bias and interobserver variability, which led to the development of quantitative coronary angiography (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29479?source=see_link\">",
"     \"Quantitative coronary angiography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24165?source=see_link\">",
"     \"Quantitative coronary angiography: Technical issues\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Coronary angiography is also limited by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical limitations such as the occasional inability to optimally visualize a particular location",
"     </li>",
"     <li>",
"      Providing information only about the contour of the vascular lumen. The components of the vascular wall are not visualized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intravascular imaging techniques of optical coherence tomography (OCT), intravascular ultrasound (IVUS), and coronary angioscopy (CA) provide information above and beyond that provided by x-ray coronary angiography (",
"    <a class=\"graphic graphic_table graphicRef78966 \" href=\"mobipreview.htm?34/18/35116\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will discuss the technical aspects, the derived information, and the clinical applications of OCT, IVUS, and CA. An attempt will be made to provide guidance on when each procedure should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321555002\">",
"    <span class=\"h2\">",
"     Arterial wall structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to understand these imaging techniques, the interpreter must first be familiar with normal arterial wall structure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intima is the inner layer that is in direct contact with the intraluminal space. The intima is normally only one to two cell layers thick, but can greatly thicken with the formation and growth of atherosclerotic plaque. It is separated from the media by the internal elastic lamina.",
"     </li>",
"     <li>",
"      The media is the middle layer of the arterial wall, and consists predominantly of homogenous layers of smooth muscle cells, which regulate vascular tone. It is separated from the adventitia by the external elastic lamina.",
"     </li>",
"     <li>",
"      The adventitia surrounds the media and is composed of fibrous connective tissue adding external support for the vessel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553541\">",
"    <span class=\"h1\">",
"     INTRAVASCULAR ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular ultrasound (IVUS) allows visualization of the coronary arterial wall by utilizing a miniature transducer at the end of a flexible catheter which emits ultrasound in the 10 to 40 MHz range. IVUS has become particularly useful in delineating plaque morphology and distribution, and providing a rationale to guide transcatheter coronary interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553548\">",
"    <span class=\"h2\">",
"     Technology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of IVUS catheters in use today: mechanical and phased array (",
"    <a class=\"graphic graphic_figure graphicRef82734 \" href=\"mobipreview.htm?29/61/30672\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common IVUS catheter utilizes a single mechanical transducer mounted at the tip, which quickly rotates to visualize the entire vessel in cross-section. The mechanical transducer has the advantage of a simple design with less complicated technology and a greater signal-to-power output. Thus, the image quality tends to be better with an overall resolution (with current 40 MHZ transducers) of 100 to 150 micrometers.",
"      <br/>",
"      <br/>",
"      The disadvantage of mechanical transducers is the central drive shaft which decreases flexibility and prevents the concurrent use of a central guidewire. These catheters may therefore be more difficult to use in tortuous vessels.",
"     </li>",
"     <li>",
"      Phased array catheters use multiple transducer elements permanently mounted along the circumference of the catheter tip. Each element sends and receives ultrasound from a sector; multiple sectors are incorporated to produce a cross-sectional image of the vessel. Phase array catheters, however, require complex programming and have suffered in image quality. Nevertheless, with the advent of higher speed computers, sophisticated software, and additional elements mounted on the catheter tip, the phased array images have made great strides within the last few years and are producing images competitive with those from mechanical transducers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most disposable IVUS transducers are oriented at a 90&deg; angle to the length of the catheter; as a result, IVUS images are displayed as cross-sectional views of the coronary artery (",
"    <a class=\"graphic graphic_figure graphicRef78872 graphicRef55075 \" href=\"mobipreview.htm?4/10/4259\">",
"     figure 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69204 graphicRef56480 \" href=\"mobipreview.htm?41/26/42405\">",
"     image 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553583\">",
"    <span class=\"h2\">",
"     The IVUS image",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound transmitted from the transducer will \"bounce\" back whenever it encounters an interface of different acoustic impedance. Acoustic impedance is primarily dependent upon the density of the tissue. Therefore, ultrasound emitted from the transducer will traverse the blood with minimal reflection but will be highly reflected when it meets the intima.",
"   </p>",
"   <p>",
"    The reflected ultrasound from the intima is displayed as a single concentric echo (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69204 graphicRef56480 \" href=\"mobipreview.htm?41/26/42405\">",
"     image 1A-B",
"    </a>",
"    ). All of the ultrasound, however, is not reflected by the intima; some will penetrate through to the media. Since the media is composed primarily of homogeneous smooth muscle cells, ultrasound passes through with minimal reflection and appears as a dark zone devoid of echoes.",
"   </p>",
"   <p>",
"    The next layer, the adventitia, is highly reflective because it has numerous collagen fibers laid down in parallel, thereby producing multiple interfaces from which to reflect sound. The adventitia will therefore appear very bright.",
"   </p>",
"   <p>",
"    As a result, the normal coronary anatomy produces alternating bright and dark echoes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A bright echo from the intima",
"     </li>",
"     <li>",
"      A dark zone from the media",
"     </li>",
"     <li>",
"      Multiple bright echoes from the adventitia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This pattern is called the normal \"three layer appearance\" of a coronary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The three-layer appearance is actually a simplified view since the IVUS resolution (approximately 120 micrometers) is not sufficient to detect the truly nondiseased intima (one or two cell layers thick or approximately 50 micrometers). Nonetheless, the intima is considered essentially normal if there is only a single thin concentric echo within the media. As the atherosclerotic disease accumulates, the intimal zone will thicken on the IVUS image (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56480 \" href=\"mobipreview.htm?6/20/6464\">",
"     image 1B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63723 \" href=\"mobipreview.htm?42/15/43248\">",
"     image 2",
"    </a>",
"    ). The anechoic (lack of echoes) media outlines the size a blood vessel would be if there were no intimal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553590\">",
"    <span class=\"h3\">",
"     Ultrasonic image of an atherosclerotic plaque",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon viewing IVUS images, plaque extent, morphology, and distribution become immediately apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The tomographic cross-sectional view of the artery is ideal to discern concentric from eccentric plaque distribution. This feature makes IVUS far more accurate than angiography for assessing plaque eccentricity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another aspect of plaque distribution is the visualization of small splits in the plaque that occur spontaneously or after a coronary intervention. Plaque fissures historically were an important part of the balloon angioplasty mechanism for luminal enlargement and were associated with a favorable outcome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76521 \" href=\"mobipreview.htm?17/18/17696\">",
"     image 3",
"    </a>",
"    ). Small plaque fissures differ from large dissections, which extend to the media and can occur at the stent edge, and are associated with adverse outcomes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76521 \" href=\"mobipreview.htm?17/18/17696\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Information about plaque composition is also available from IVUS, since denser material (calcium) will reflect more ultrasound and appear brighter on the video monitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/1\">",
"     1",
"    </a>",
"    ]. Calcium is so dense that none of the ultrasound waves penetrate to deeper tissues, producing an acoustic shadow, which is a hallmark of calcification. Alternatively, a plaque that is less echodense than the collagen-rich adventitia is described as a \"soft\" plaque. This is the classic approach of using grey scale images to determine plaque composition. Plaque composition influences interventional approach; as an example, rotablator is particularly effective against calcified plaques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Besides the classic grey scale interpretation of plaque characteristics, there has been active investigation attempting to get more precise plaque composition information from IVUS images. Kawasaki and colleagues from Japan have published several studies whereby they analyze the integrated backscatter (IB) signal from the radiofrequency (RF) signal of ultrasound and, based on the IB IVUS image, color code the plaque for different plaque compositions (",
"    <a class=\"graphic graphic_figure graphicRef79023 \" href=\"mobipreview.htm?34/20/35137\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This technique has undergone pathologic validation and has shown changes in plaque composition with aggressive statin therapy.",
"   </p>",
"   <p>",
"    Another approach has been to look both at the amount of returning RF signal and how that RF signal was distorted by the plaque. These changes are then put through an algorithm established from known plaque tissue types to determine the plaque composition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/6\">",
"     6",
"    </a>",
"    ]. Again, the final interpretation is color coded and superimposed onto the grey scale image. This technique has been commercialized and trademarked as \"Virtual Histology.\" This technique is currently under investigation in different patient populations and in natural history studies.",
"   </p>",
"   <p>",
"    Because of its high resolution, IVUS can precisely determine vessel and plaque size (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63723 \" href=\"mobipreview.htm?42/15/43248\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/7\">",
"     7",
"    </a>",
"    ]. Angiography permits measurement of luminal diameters typically in 2 or 3 orthogonal views; in contrast, IVUS provides a tomographic view (180 potential diameters) and therefore a more accurate assessment of size. Thus, the true minimal and maximal luminal diameter can be obtained with IVUS along with cross-sectional area measurements of both the lumen and vessel. IVUS has also provided information that the cross-sectional area of the plaque remains constant during vasomotion of the coronary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to a discussion of the applications of IVUS, it is important to appreciate the added information provided by this procedure when compared with conventional x-ray coronary angiography for the assessment of coronary artery disease (",
"    <a class=\"graphic graphic_table graphicRef78966 \" href=\"mobipreview.htm?34/18/35116\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553604\">",
"    <span class=\"h3\">",
"     Men versus women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women have a higher mortality than men after coronary interventions; it is uncertain if this is due to qualitative differences in atherosclerosis. One study of patients with chronic angina compared IVUS findings in 169 women to those in 549 men and reported that when corrected for body surface area, women had similar external elastic membrane and luminal cross sectional areas and similar plaque burden, eccentricity, and calcium density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/9\">",
"     9",
"    </a>",
"    ]. However, these assessments were done in a variety of different vessels. When only the proximal left anterior descending (LAD) or left main coronary arteries were studied, women tended to have a smaller lumen and external elastic membrane (media size) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/10\">",
"     10",
"    </a>",
"    ]. This finding has been corroborated in an IVUS study of heart transplants in which coronary arteries from a female donor became larger when placed into a male recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/11\">",
"     11",
"    </a>",
"    ]. There appears to be a gender-specific factor that alters coronary artery size, independent of body or heart size.",
"   </p>",
"   <p>",
"    Another study found morphologic plaque differences between men and women. Men had denser, more calcified plaques than women, suggesting an earlier onset of plaque development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553611\">",
"    <span class=\"h3\">",
"     Comparison with coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of coronary arterial lesions is traditionally performed using x-ray coronary angiography (",
"    <a class=\"graphic graphic_table graphicRef78966 \" href=\"mobipreview.htm?34/18/35116\">",
"     table 1",
"    </a>",
"    ). With coronary angiography (",
"    <a class=\"graphic graphic_table graphicRef78966 \" href=\"mobipreview.htm?34/18/35116\">",
"     table 1",
"    </a>",
"    ) radiopaque contrast material is injected into the coronary artery and the lumen is imaged since the lumen appears dense to x-rays, while the arterial wall is opaque. The lumen \"shadow-o-gram\" is a fairly imprecise measure of luminal morphology and size (with an optimal resolution of approximately 0.3 mm) (",
"    <a class=\"graphic graphic_figure graphicRef66256 \" href=\"mobipreview.htm?7/36/7759\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/13\">",
"     13",
"    </a>",
"    ]. Because of the limitations of angiography, hazy angiographic sites could represent an irregular",
"    <span class=\"nowrap\">",
"     plaque/distorted",
"    </span>",
"    lumen, a napkin-ring lesion, thrombus, or a dissection. IVUS is particularly useful in this situation because it immediately distinguishes between plaque and lumen irregularities, dissection, or discrete stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76521 \" href=\"mobipreview.htm?17/18/17696\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IVUS has also demonstrated that apparently normal areas by angiography are often markedly abnormal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76452 \" href=\"mobipreview.htm?19/42/20143\">",
"     image 4",
"    </a>",
"    ). This is particularly true for smaller coronary arteries. In one study, for example, IVUS detected calcium in 73 percent of lesions in arteries with an angiographic reference lumen diameter &lt;2 mm; angiography had a sensitivity of only 39 percent for detecting calcium in these vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography is often limited in its ability to assess the extent of atherosclerotic disease because of [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The diffuse nature of atherosclerosis",
"     </li>",
"     <li>",
"      Complex luminal shapes",
"     </li>",
"     <li>",
"      Compensatory enlargement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553618\">",
"    <span class=\"h4\">",
"     Diffuse lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Normal\" references by angiography may have as much as one-third of their cross-sectional area filled with plaque as determined by IVUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If the diffuse plaque is evenly distributed throughout the blood vessel without a focal encroachment on the lumen, it will not be detected by angiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76452 \" href=\"mobipreview.htm?19/42/20143\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72154 \" href=\"mobipreview.htm?37/15/38143\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, IVUS has changed our perception of an angiographic stenosis. We no longer assume that the nonstenotic region surrounding a discrete stenosis is normal. If the reference segment is also filled with plaque, the plaque burden at the stenosis would be more severe than angiographically apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553625\">",
"    <span class=\"h4\">",
"     Complex luminal shapes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experienced angiographers know that a stenosis with different severities in multiple views is an eccentric lesion. However, highly irregular lesions may not be fully appreciated in multiple views. Tomographic images may be needed to display the true luminal shape for very irregular plaques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321553632\">",
"    <span class=\"h4\">",
"     Compensatory enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;An artery is a living structure that can change and adapt. A pathologic study found that coronary arteries will enlarge to accommodate focal plaque deposition in an attempt to maintain luminal integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/19\">",
"     19",
"    </a>",
"    ]. Since successful compensatory enlargement will preserve the luminal contour, there will be no angiographic stenosis (since the angiogram cannot see beyond the lumen) despite the deposition of a significant plaque (",
"    <a class=\"graphic graphic_figure graphicRef74983 \" href=\"mobipreview.htm?34/53/35665\">",
"     figure 5",
"    </a>",
"    ). On the other hand, failure to compensate can lead to a greater degree of luminal stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/20\">",
"     20",
"    </a>",
"    ]. Such lesions may also have a smaller minimum luminal and reference diameters after directional coronary atherectomy compared to those with compensatory enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IVUS can detect both the vessel expansion (enlargement in the media to media diameter) and the focal plaque burden. As an example, one IVUS study of 65 patients reported that three patterns accounted for 89 percent of all atherosclerotic arterial segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concentric plaque with a circular lumen and a circular external elastic lamina",
"     </li>",
"     <li>",
"      Eccentric plaque with a circular lumen and an oval external elastic lamina",
"     </li>",
"     <li>",
"      Eccentric plaque with an oval lumen and a circular external elastic lamina",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A circular lumen was preserved in 66 percent of all atherosclerotic arterial segments and failure to maintain a circular lumen is possibly associated with the development of a stenotic lesion at a specific site on the artery.",
"   </p>",
"   <p>",
"    The presence or absence of compensatory enlargement also can determine the mechanism of response to angioplasty. Coronary arteries with compensatory enlargement show an improvement in lumen area, primarily through a reduction in plaque size without a change in vessel area; in contrast, arteries without compensatory enlargement achieve their gain in lumen area by arterial stretch without a change in plaque size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321554924\">",
"    <span class=\"h2\">",
"     IVUS clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical applications of IVUS, such as optimal stent placement, clarifying the severity of intermediate coronary stenoses seen on coronary angiography, and detecting cardiac allograft vasculopathy are discussed separately in the appropriate topic reviews. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link&amp;anchor=H12#H12\">",
"     \"General principles of the use of intracoronary stents\", section on 'IVUS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13672?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\", section on 'Intermediate severity stenosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18585?source=see_link&amp;anchor=H12357216#H12357216\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\", section on 'Intravascular ultrasound'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H321552326\">",
"    <span class=\"h1\">",
"     OPTICAL COHERENCE TOMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optical coherence tomography (OCT) relies on the backscattering (reflection) of light (in the 1300nm range) wavelength to obtain cross-sectional images of tissue. When applied to the coronary circulation, OCT has a tenfold higher image resolution than intravascular ultrasound (IVUS). This allows imaging of the coronary artery in great detail and potentially providing unique insights into coronary artery pathophysiology.",
"   </p>",
"   <p>",
"    These advantages render OCT a recognized research tool for the assessment of atherosclerosis and useful tool for assessment of the adequacy of placement of coronary stents. OCT can be used for indications similar to the ones established for intravascular ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/24\">",
"     24",
"    </a>",
"    ], and, can also be used for clinical decision making in patients with acute coronary syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683160\">",
"    <span class=\"h2\">",
"     Technology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683168\">",
"    <span class=\"h3\">",
"     Imaging principle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physics of OCT (",
"    <a class=\"graphic graphic_table graphicRef78966 \" href=\"mobipreview.htm?34/18/35116\">",
"     table 1",
"    </a>",
"    ) is analogous to pulse-echo ultrasound imaging, but light is used rather than sound to create the image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/26\">",
"     26",
"    </a>",
"    ]. Whereas ultrasound produces images from backscattered (reflected) sound \"echoes,\" OCT uses infrared light waves (approx 1300nm wavelength) that reflect off the internal microstructure within the biological tissues.",
"   </p>",
"   <p>",
"    Both the bandwidth of the infrared light used and the wave velocity are orders of magnitude higher than in medical ultrasound. The resulting resolution is one order of magnitude larger than that of IVUS: the axial resolution of OCT is about 15 &mu;m, the lateral resolution is approximately 25 &micro;m. However, the imaging depth of approximately 1.0 to 1.5mm within the coronary artery wall is less than that of IVUS.",
"   </p>",
"   <p>",
"    Analogous to ultrasound imaging, the echo time delay between emission and receipt of the light is used to generate spatial image information, the intensity of the received (reflected or backscattered) light is translated into a (false) color scale. As the speed of light is much faster than that of sound, an interferometer is required to measure the backscattered light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/27\">",
"     27",
"    </a>",
"    ]. The interferometer splits the light source into two &ldquo;arms,&rdquo; a reference arm and a sample arm, which is directed into the tissue. The light from both arms is recombined at a detector, which registers the so-called interferogram, the sum of reference and sample arm fields. Because of the large source bandwidth, the interferogram is non-zero only if the sample and reference arms are of equal length, within a small window equal to the coherence length of the light source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683177\">",
"    <span class=\"h3\">",
"     Time domain OCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;First generation OCT used for intracoronary imaging employed &lsquo;time-domain&rsquo; technology. Relatively slow data acquisition and the need to clear the artery from blood during image acquisition resulted in a complex imaging procedure, limited its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683193\">",
"    <span class=\"h3\">",
"     Fourier domain OCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 2008, a new generation of OCT systems, also called Fourier domain OCT systems, have been available for widespread clinical use. With these systems, the interferogram is detected as a function of wavelength, either by using a broadband source as in the time domain systems, and spectrally resolved detection, or alternatively by incorporating a novel wavelength-swept laser source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This latter technique is also called &ldquo;swept-source OCT,&rdquo; or optical frequency domain imaging (OFDI).",
"   </p>",
"   <p>",
"    From the signal received in one wavelength sweep, the depth profile can be constructed by the Fourier transform operation. Most signals can be thought of as a summation of sine waves with different frequencies. The Fourier transform extracts those frequencies, and their relative weights, from the signal. The source wavelength in Fourier-domain OCT can be swept at a much higher rate than the position scan of the reference arm mirror in a time-domain OCT system. This development has led to faster image acquisition speeds, with greater penetration depth, without loss of vital detail or resolution, and represents a great advancement on current conventional OCT systems. Coronary arteries can be imaged with high OCT catheter pullback speeds within seconds, which allows for widespread clinical use in a broad range of patients and lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683210\">",
"    <span class=\"h2\">",
"     OCT imaging technique",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683218\">",
"    <span class=\"h3\">",
"     OCT imaging catheters and imaging procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCT imaging catheters contain an OCT imaging core at their distal tip (",
"    <a class=\"graphic graphic_picture graphicRef82662 \" href=\"mobipreview.htm?8/31/8693\">",
"     picture 1",
"    </a>",
"    ). Similar to IVUS, the imaging core is oriented at 90 degree angle to the length of the catheter; and is rotated during imaging. As a result, OCT images are displayed similar to IVUS as cross-sectional views of the coronary artery. Automated pullback of the OCT imaging core allows the user to scan through the coronary artery.",
"   </p>",
"   <p>",
"    Intracoronary OCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/31\">",
"     31",
"    </a>",
"    ] is performed by introducing the small (2.7 French) imaging catheter over a guide wire (0.014 inch) distally into the coronary artery using standard guide catheters (6F or larger). A motorized pullback is performed to scan the coronary artery segment. The pullback speed is typically 20",
"    <span class=\"nowrap\">",
"     mm/sec",
"    </span>",
"    with a frame rate of 100 frames per second or higher. Since blood scatters the OCT signal, it is temporarily cleared by an injection of x-ray contrast medium during the duration of the OCT pullback (typical flush rate",
"    <span class=\"nowrap\">",
"     3.0&nbsp;ml/s).",
"    </span>",
"    A variety of solutions, warmed to 37&deg; C have been used alternatively as flush medium, including Lactated Ringer&rsquo;s, viscous iso-osmolar contrast media, and mixtures of lactated Ringer&rsquo;s and contrast media or low molecular weight dextrose. The time needed to image a 50mm artery segment is typically three seconds with a total volume of x-ray contrast of 10 to 12 ml, which is comparable to the amount of x-ray contrast needed for a single angiographic run.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683227\">",
"    <span class=\"h3\">",
"     Patient and lesion selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;All epicardial coronary arteries and venous or arterial grafts that are accessible by a guiding catheter are eligible for OCT imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/32\">",
"     32",
"    </a>",
"    ]. OCT should not be performed in patients with severely impaired left ventricular function or those presenting with severe hemodynamic compromise, as the imaging procedure might induce brief ischemia. Further, OCT should be used with caution in patients with single remaining vessel, as any guidewire or catheter insertion carries a small risk of dissection or arterial spasm, or those with markedly impaired renal function. In these clinical circumstances, the gain in diagnostic accuracy must be balanced against potential adverse effects in individual patients.",
"   </p>",
"   <p>",
"    A technical draw-back is that plaques located at the very ostium of the left or right coronaries cannot be accurately addressed by OCT, as it is difficult to clear the artery from blood during a nonselective guide catheter position, required for the visualization of the ostium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683236\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The applied energies in contemporary, intravascular OCT are relatively low (output power in the range of 5.0 to 8.0 mW) and are not thought to cause functional or structural damage to the tissue.",
"   </p>",
"   <p>",
"    The principle safety considerations relate to the possible induction of ischemia due to the need of blood displacement for image acquisition. Current OCT systems allow for very fast data within a few seconds and therefore are unlikely to lead to significant ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/33\">",
"     33",
"    </a>",
"    ]. In a report of 114 OCT acquisitions in 90 patients, the procedure was successful in 89. No patients suffered contrast induced nephropathy and no major complications were recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/34\">",
"     34",
"    </a>",
"    ]. One patient had a transient vessel spasm that was resolved with intracoronary administration of nitrates. During FD-OCT images acquisition no ischemic ECG changes occurred. Ventricular ectopic beats were found only in three patients while other major arrhythmias (ventricular tachycardia or fibrillation) were not observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683245\">",
"    <span class=\"h3\">",
"     Concomitant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to other diagnostic coronary instrumentation such as IVUS, patients should be anticoagulated (typically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) during the OCT procedure. The OCT catheter should be introduced distally into the coronary artery after the administration of intracoronary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    to minimize the potential for catheter-induced vasospasm.",
"   </p>",
"   <p>",
"    Some clinicians prefer to prescribe dual antiplatelet therapy for 14 days or up to one month after OCT imaging, as invasive imaging has been shown to cause limited endothelial damage in animal experimental studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683254\">",
"    <span class=\"h2\">",
"     The OCT image",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683262\">",
"    <span class=\"h3\">",
"     Normal coronary morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCT creates cross-sectional images of the coronary artery wall, based on the optical interaction of the emitted light with the vessel wall. Light is typically reflected and backscattered in biological structures with different optical indices. In normal coronary arteries, light is highly reflected by the internal external elastic membranes. As a result, the normal coronary artery wall appears as a circular structure with three concentric layers at OCT images (",
"    <a class=\"graphic graphic_picture graphicRef57928 \" href=\"mobipreview.htm?5/36/5704\">",
"     picture 2",
"    </a>",
"    ). The innermost signal-rich layer reflects the internal elastic membrane, the middle dark layer represents the media is and the outer, signal rich layer represents the external elastic lamina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H321555002\">",
"     'Arterial wall structure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A normal three-layer appearance by OCT is not synonymous to three-layer appearance by IVUS. While OCT (resolution approx 15 &mu;m) is able to visualize a normal, nondiseased coronary artery, the resolution of IVUS (approx 120 &mu;m) is not able to visualize truly nondiseased vessels (",
"    <a class=\"graphic graphic_figure graphicRef67124 \" href=\"mobipreview.htm?40/1/40978\">",
"     figure 6",
"    </a>",
"    ). Thus, OCT can confirm the absence of significant atherosclerosis or indicate the degree of subclinical atherosclerotic lesion formation. Serial measurements can be performed to monitor the structural changes that occur in the vessel wall over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683271\">",
"    <span class=\"h3\">",
"     Atherosclerotic plaques",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCT has the ability to characterize the structure and extent of coronary artery disease in greater detail than IVUS or angioscopy (",
"    <a class=\"graphic graphic_figure graphicRef82412 \" href=\"mobipreview.htm?24/59/25530\">",
"     figure 7",
"    </a>",
"    ). The various components of atherosclerotic plaques have different optical properties. Typically, OCT images are interpreted by visual assessment of the signal intensity and geometry. Good inter- and intraobserver agreement for visual plaque characterization using criteria as described below have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Compared to IVUS, OCT has a higher accuracy to detect early atherosclerosis, necrotic core or lipid-rich tissues, a higher accuracy to detect thrombi and allows for visualization of calcifications without blooming artefact, which typically causes overestimation of the calcium extent by IVUS.",
"   </p>",
"   <p>",
"    When atherosclerotic lesions are present, OCT can provide details on the tissue composition. The following classifications have been used and validated using in-vitro studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrous plaques are typically rich in collagen or muscle cells and have a homogeneous OCT signal. Calcifications within plaques are identified by the presence of well delineated, low back scattering, signal-poor heterogeneous regions.",
"     </li>",
"     <li>",
"      Necrotic cores or lipid-rich tissues are less well-delineated than calcifications, appearing as diffusely-bordered, signal-poor regions with overlying signal-rich bands, corresponding to fibrous caps. The superiority of OCT for lipid-rich plaque detection has been confirmed in other studies comparing OCT, IVUS and IVUS derived techniques for plaque composition analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/35,39\">",
"       35,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A specific type of plaque is called the thin-cap fibroatheroma. Thin fibrous cap atheroma are considered the most important morphologic substrate for a plaque at high risk to rupture and causing acute coronary syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20729?source=see_link&amp;anchor=H13450322#H13450322\">",
"       \"Pathology and pathogenesis of the vulnerable plaque\", section on 'Thin-cap fibroatheroma (vulnerable plaque)'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      OCT allows the diagnosis of thin fibrous cap atheroma with a sensitivity of 90 percent and a specificity of 79 percent when compared to histopathology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/40\">",
"       40",
"      </a>",
"      ] and for accurate measurement of the fibrous cap thickness with low variability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Ongoing research suggests that the ability of OCT to measure changes in the fibrous cap thickness could be used to monitor the effect of therapeutic agents aiming at plaque stabilization (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69676 \" href=\"mobipreview.htm?37/19/38200\">",
"       image 6",
"      </a>",
"      ). Exploratory registries evaluating the fibrous cap thickness in patients on statin therapy suggest a trend towards an increased cap thickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/43\">",
"       43",
"      </a>",
"      ] and lower incidence of plaque rupture under statin therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/44\">",
"       44",
"      </a>",
"      ]. Such data, however, need to be confirmed by adequately powered, prospective studies.",
"     </li>",
"     <li>",
"      Thrombi are identified as masses protruding into the vessel lumen discontinuous from the surface of the vessel wall. Red thrombi consist mainly of red blood cells; relevant OCT images are characterized as high-backscattering protrusions with signal-free shadowing. White thrombi consist mainly of platelets and white blood cells and are characterized by a signal-rich, low-backscattering billowing projections protruding into the lumen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/41\">",
"       41",
"      </a>",
"      ]. OCT is highly sensitive in diagnosing intracoronary thrombi, as the high contrast between the lumen and the surrounding structures facilitate the diagnosis. This is in contrast to IVUS were it is often difficult to differentiate thrombi from the blood filled lumen.",
"     </li>",
"     <li>",
"      Less well validated entities are local macrophage accumulations and neovascularization. Macrophages can be seen by OCT as signal-rich, distinct or confluent punctate dots that exceed the intensity of background speckle noise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/45\">",
"       45",
"      </a>",
"      ]. They may be seen at the boundary between the bottom of the cap and the top of a necrotic core.",
"     </li>",
"     <li>",
"      Due to its high spatial resolution, OCT is the only technique able to detect eroded plaques [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/46\">",
"       46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Likewise, experts believe that the visualization of vasa vasorum and neovascularization is possible; however, no substantial validation studies have been published. Neovascularization within the intima appears as signal poor voids that are sharply delineated and usually contiguous and seen on multiple frames [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683288\">",
"    <span class=\"h3\">",
"     Assessment of acute stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVUS has been used to assess the acute result following stenting (",
"    <a class=\"graphic graphic_picture graphicRef60013 \" href=\"mobipreview.htm?37/44/38600\">",
"     picture 3",
"    </a>",
"    ), giving valuable information on extent of stent expansion and apposition against the vessel wall. OCT, with its high contrast between the lumen and the vessel wall as well as the high resolution allows one to visualize stented vessels in greater detail than IVUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/48\">",
"     48",
"    </a>",
"    ]. OCT can also demonstrate periprocedural vessel trauma including coronary artery dissection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71808 \" href=\"mobipreview.htm?6/6/6249\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    From a clinical view point, a stent should be expanded with all struts apposed to the vessel wall in order to allow for optimal blood flow. However, IVUS and OCT studies have shown that stent struts are not always apposed against the coronary wall, despite a good angiographic result. The risk for stent strut malapposition might be increased in certain stent designs (thick struts, closed-cell design), in conditions where two stents have been implanted in an overlapping way in order to completely cover a long coronary lesion, and in complex lesions. When inadequate stent expansion or strut mal-apposition is recognized during the percutaneous coronary intervention procedure, it can be correct by the use of adequate balloons for further dilatation. While these findings are helpful for the improvement of future stent designs, the clinical relevance and potentially long-term sequelae of mal-apposed struts as detected by OCT are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683297\">",
"    <span class=\"h3\">",
"     Assessment of long-term stent outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term stent",
"    <span class=\"nowrap\">",
"     strut/vessel",
"    </span>",
"    wall interaction is of interest to both researchers and clinicians. The stability of the acute result, the identification of complex anatomy that is not accessible by angiography or IVUS, and the understanding of reasons for stent failures, when they do occur, are example of information that is of interest. In contrast to IVUS, OCT can reliably detect and quantify early and very thin layers of tissue coverage on stent struts, even in drug-eluting stents with very thin layers of neointima, often below 80 &mu;m in thickness, with high reliability (",
"    <a class=\"graphic graphic_picture graphicRef58375 \" href=\"mobipreview.htm?26/39/27256\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OCT has been employed in prospective clinical trials to compare the long-term outcome of various stents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The LEADERS randomized trial was a comparison of a biolimus-eluting stent (BES) with biodegradable polymer with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stent (SES) using a durable polymer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34773?source=see_link\">",
"       \"Coronary artery stent types in development\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Fifty-six consecutive patients underwent OCT during angiographic follow-up at nine months. Strut coverage at an average follow-up of nine months was significantly more complete in patients allocated to BES when compared to those with SES [weighted difference -1.4%, 95% CI, -3.7 to 0.0] [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The In the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with STEMI were randomized to paclitaxel-eluting stent (PES) or bare-metal stent (BMS) implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=see_link&amp;anchor=H24756048#H24756048\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Selection of stent type'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The OCT substudy revealed that implantation of PES as compared with BMS significantly reduced neointimal hyperplasia but resulted in higher rates of uncovered and malapposed stent struts at 13-month follow-up (1.1&plusmn;2.5 percent in BMS lesions versus 5.7&plusmn;7.0 percent in PES lesions). Likewise OCT was employed to study tissue coverage at follow-up in bioresorbable scaffolds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/52\">",
"     52",
"    </a>",
"    ]. OCT was able to visualize the particular structure of the scaffold struts, the tissue coverage over time, as well as the changes in the optical properties of the vascular tissue during the bioresorption process.",
"   </p>",
"   <p>",
"    While these observations are important to understand differences in-stent design, further studies are required to determine the clinical significance of these findings. Today, no threshold for coverage is established. However, OCT is the only imaging modality to date that offers, within the discussed limits, the possibility to understand tissue coverage and neointima formation in DES over time. Large scale, prospective studies, might be useful to address vexing clinical questions such as the relationship of drug-eluting stent deployment, vascular healing, the true time course of endothelial stent coverage and late-stent thrombosis. This may also better guide the optimal duration of dual anti-platelet therapy that currently remains unclear and rather empiric.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683306\">",
"    <span class=\"h2\">",
"     OCT clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Today, no clinical indications for OCT imaging are established. There are no randomized data supporting a prognostic role for OCT in catheter-based intervention. However, there is broad expert agreement that the detailed, easy accessible and interpretable information of OCT on the presence of atherosclerosis, its extent, lumen narrowing as well as on the result of any interventional measure can be of clinical value, at least in individual patients and in specific clinical scenarios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Preliminary data on OCT indicate that it can change the operator&rsquo;s intention-to-treat and modify the overall revascularization strategy, potentially avoiding unnecessary interventional procedures. OCT might be efficient in complex interventions including treatment of left main stem, bifurcations as well as in all cases of angiographically ambiguous lesions, and in-stent failures.",
"   </p>",
"   <p>",
"    Two other potential uses of OCT are identification of an angiographically unclear lesion and assessment of stent failure; both are discussed directly below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683315\">",
"    <span class=\"h3\">",
"     Patients with ACS and angiographically unclear culprit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of acute coronary syndromes usually relies on rapid treatment of the culprit vessel. The culprit vessel is sometimes indicated by the localization of the pathognomonic electrocardiographic changes, or by the finding of a thrombotic, hazy lesion by angiography. However, the identification of the culprit lesion can be challenging in some individuals, especially when multi-vessel disease is present. Similarly, in 15 percent of the patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction, angiography shows a patent infarct-related vessel with TIMI 3 flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/55\">",
"     55",
"    </a>",
"    ]. OCT can provide accurate information on the superficial composition of the plaque, can identify ruptured plaques and most importantly, can reveal thrombosed lesions, and thus identify the culprit lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74241 \" href=\"mobipreview.htm?1/50/1831\">",
"     image 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683324\">",
"    <span class=\"h3\">",
"     Assessment of stent failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reasons for drug eluting stent (DES) failure, including restenosis and stent thrombosis, are poorly understood. In the catheterization laboratory, OCT can be very useful in the evaluation of the causes for stent failure in any given patient and guide treatment decisions (",
"    <a class=\"graphic graphic_picture graphicRef81158 \" href=\"mobipreview.htm?16/44/17097\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/57\">",
"     57",
"    </a>",
"    ]. OCT is able to differentiate mechanical stent failure (such as incomplete stent expansion or stent fracture) from impaired healing (such as absence of strut coverage, absence of homogenous coverage, or (late) strut malapposition).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949544\">",
"    <span class=\"h1\">",
"     CORONARY ANGIOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary angioscopy (CA) is an intravascular technique that allows direct visualization (using high intensity cold light) of the internal surface of the coronary circulation. This technique provides information concerning the pathology of coronary lesions and insight into the pathophysiology of acute coronary syndromes, thereby aiding diagnosis and treatment. Due to technical limitations, CA has not become broadly incorporated into routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949551\">",
"    <span class=\"h2\">",
"     Imaging technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angioscope is a disposable coronary polyethylene catheter with a 4.5 French (1.5 mm) outer diameter that can be inserted through an 8 French percutaneous coronary intervention (PCI) guiding catheter.",
"   </p>",
"   <p>",
"    The catheter consists of two coaxial catheters. The inner catheter contains the optical fibers, and a small secondary channel permits inflation of a low-pressure occlusion balloon, or cuff, located at the tip of the outer catheter. The main lumen of the outer catheter is used for irrigation. The fluid exits the catheter just distal to the occlusion cuff.",
"   </p>",
"   <p>",
"    An optical coupler connects the proximal image bundle aperture to the camera and to the light source. The combination of several features, such as field of view, scope flexibility, and the moving optical bundle during imaging, provides excellent image resolution. Lack of a mechanism to steer the lens tip remains an important limitation, particularly in large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tortuous vessels.",
"   </p>",
"   <p>",
"    A 0.014 inch PCI guidewire is first inserted through an 8 French guiding catheter and positioned distally in the target artery. To permit optimal guidance of the lens tip and avoid wire-trapping in tortuous vessels, we prefer the use of guidewires that offer more support than \"floppy\" wires.",
"   </p>",
"   <p>",
"    The angioscope is carefully advanced over the guidewire and irrigation is begun to eliminate air bubbles before advancing into the coronary artery. Under fluoroscopy, the angioscope is then advanced into the coronary artery and the occlusion cuff is positioned at the selected site. While keeping the occlusion cuff inflated, this catheter can be advanced or withdrawn 5 cm over the guidewire inside the outer catheter",
"   </p>",
"   <p>",
"    Irrigation is then started and the occlusion cuff is inflated after two to five seconds. As soon as a satisfactory image is obtained, the inflation is stopped, recording on videotape is started, and the probing fiber is slowly advanced over the guidewire under continuous irrigation.",
"   </p>",
"   <p>",
"    Since the combination of proximal occlusion and irrigation produces myocardial ischemia and chest pain, it is advisable to limit each inflation to 30 seconds. The procedure can be repeated after a brief interval of balloon deflation and coronary reperfusion with blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949572\">",
"    <span class=\"h3\">",
"     Lesion selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, the primary clinical indication for performing CA is to evaluate, in detail, specific characteristics of a coronary lesion of interest. This is usually determined by evaluating the coronary angiograms performed prior to angioscopy. Often, lesions potentially associated with an ongoing acute coronary syndrome would be ideal candidates. There are no guideline indications for angioscopy.",
"   </p>",
"   <p>",
"    The proximal 2 cm of all three major coronary arteries cannot be imaged because of the relatively large distance between the occlusion cuff and the lens tip. As a result, the angioscope is ideal to visualize the midsegments of the main divisions and also large side branches. If the internal luminal diameter is between 2.5 and 3.5 mm, imaging is usually excellent for the entire vessel. As the vessel diameter increases beyond 3.5 mm, the quality of the imaging decreases. In addition, if the left circumflex artery is excessively tortuous and has a sharp takeoff, it is better to avoid visualization of the vessel because the main catheter body is quite stiff. During the procedure, it is recommended to keep the occlusion cuff straight to avoid an eccentric and wall directed field of view.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949579\">",
"    <span class=\"h2\">",
"     Correlation with histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A close correlation is observed between the findings from histopathology and those obtained with CA. One study evaluated 70 postmortem coronary artery segments by angioscopy, intracoronary ultrasound, and histologic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/58\">",
"     58",
"    </a>",
"    ]. Angioscopic findings were classified as normal artery, stable atheroma, disrupted atheroma, and thrombus. Using histologic findings as reference, angioscopy had a sensitivity and specificity of 95 percent for all pathologic findings except for disrupted atheroma, a lesion occasionally missed by this technique. However, the sensitivity of angioscopy for thrombus was excellent (100 percent) and vastly superior to that of ultrasound (57 percent).",
"   </p>",
"   <p>",
"    Since there was a lack of consensus in reporting the qualitative type of imaging because of subjectivity in interpretation, it became necessary to establish a classification of angioscopic findings. In October 1992, European angioscopy investigators established a simplified \"Ermenonville\" classification based upon an unbiased review of videotapes by several angioscopy investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/59\">",
"     59",
"    </a>",
"    ]. The classification system is often used to assist in the clinical documentation of angioscopy results. The following parameters are described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Image quality",
"     </li>",
"     <li>",
"      Obtained image of the target vessel",
"     </li>",
"     <li>",
"      Normal vessel",
"     </li>",
"     <li>",
"      Narrowing",
"     </li>",
"     <li>",
"      Shape of narrowing",
"     </li>",
"     <li>",
"      Thrombus",
"     </li>",
"     <li>",
"      Atheroma",
"     </li>",
"     <li>",
"      Postangioplasty dissection",
"     </li>",
"     <li>",
"      Wall hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949586\">",
"    <span class=\"h2\">",
"     The CA image",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioscopy visualizes the inner lumen of the coronary artery wall and intraluminal changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949593\">",
"    <span class=\"h3\">",
"     Normal coronary artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal coronary artery surface is smooth in contour, without any protruding structure, and has a uniform yellow-white or grayish-white color.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949600\">",
"    <span class=\"h3\">",
"     Abnormal coronary findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal findings in the coronary artery include the presence of atheroma, thrombus, dissection, subintimal hemorrhage, luminal narrowing, and restenosis. Coronary stents, and the degree which they have been endothelialized, can also be analyzed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949607\">",
"    <span class=\"h4\">",
"     Atheroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atheroma are usually yellow, and may be smooth and lining the lumen, or protruding. A fibrous plaque is a white, nonmobile elevation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protrusion that is focal or diffuse. If the atheroma is complicated, it may or may not be mobile, patchy colored, and with or without visible cracks or fissures on the luminal surface. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20729?source=see_link&amp;anchor=H13450283#H13450283\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\", section on 'Pathology of coronary atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949614\">",
"    <span class=\"h4\">",
"     Thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombi are defined as masses that are red, white or both, and adhere to the intima",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protrude into the lumen. Thrombi are, by definition, not located within the wall but on its surface. Intracoronary thrombi may vary in size from small patches on the surface to large, protruding, and obstructing masses. This mass is not dislodged by Ringer lactate infusion. Pathologic studies of coronary thrombi have shown that white thrombi are platelet-rich, whereas red thrombi contain an abundance of fibrin mixed with erythrocytes and platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949621\">",
"    <span class=\"h4\">",
"     Dissections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissections, mostly encountered after balloon angioplasty, range in size from small surface disruptions to those that are wide and long.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949628\">",
"    <span class=\"h4\">",
"     Subintimal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subintimal hemorrhage can be defined as a patch of red coloration within the arterial wall. It can be difficult to distinguish from red lining thrombus. Subintimal hemorrhage is usually observed after balloon angioplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949635\">",
"    <span class=\"h4\">",
"     Luminal narrowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioscopy is not a good technique for quantitative evaluation of luminal narrowing. Nevertheless, for high-grade stenosis, the coronary guidewire that passes through the stenosis may give a usable visual reference. As an example, a lumen that can contain only one or two 0.014\" (0.36 mm) wires would have a minimal luminal diameter of 0.72 mm or less, and should be considered an important stenosis. This method has been evaluated by the European Working Group, and has been found to have limited value because of a large intra- and inter-observer variability. However, CA can recognize a total occlusion and the presence or absence of narrowing. Therefore, at present, angioscopy is not an ideal tool for visual estimation or automated quantification of coronary artery narrowings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949642\">",
"    <span class=\"h4\">",
"     Restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restenosis with angioscopy has a white, smooth appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949649\">",
"    <span class=\"h4\">",
"     Stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracoronary stents can be easily visualized by angioscopy; many stents have been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. However, insertion of the angioscope into any stent over a wire and crossing into a side branch is not recommended, since the lens tip assembly can get trapped behind these wire crossings and dislocate the stent. The warning relates to any stent placed at any time. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949656\">",
"    <span class=\"h2\">",
"     CA clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA has been utilized to help understand",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evaluate several different clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consequences of different interventional cardiology techniques",
"     </li>",
"     <li>",
"      Cardiac transplant vasculopathy",
"     </li>",
"     <li>",
"      Pathophysiology of various coronary syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949677\">",
"    <span class=\"h3\">",
"     Coronary stent implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA has been used as an adjunctive technique during bare metal stent implantation, either guiding the intervention or leading to a modification of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/62,65\">",
"     62,65",
"    </a>",
"    ]. In one study of 15 patients, angioscopy was performed to evaluate the results of stent placement. Thrombus, undetected by angiography, was found in two cases, while four patients had residual narrowing requiring redilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/62\">",
"     62",
"    </a>",
"    ]. In an additional two patients, angioscopy was performed because of stent restenosis, which was initially thought to be due to thrombus formation. In both cases, angioscopy revealed that the restenosis was due to subtotal occlusion because of fibrotic tissue and thrombus, thereby obviating the use of thrombolytic therapy. Thus, the findings on angioscopy affected some aspect of management in over one-half of patients.",
"   </p>",
"   <p>",
"    Angioscopy has also been used to evaluate the time course of neointimal coverage of bare metal stents. One study performed angioscopy before, immediately after, at seven days, and two months after stent implantation in 20 patients treated with either antiplatelet agents or anticoagulation. In the majority of patients, neointimal formation was completed by two months after stent placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/63\">",
"     63",
"    </a>",
"    ]. In a second series of 14 patients who underwent angioscopy immediately after stent placement, at 8 to 45 days, and at 65 to 142 days, three types of neointimal layer were observed: a white layer with a cotton-like surface, a white layer with a smooth surface, and a transparent layer with a smooth surface. Approximately three months were required for the completion of coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time course of neointimal coverage is much slower with drug-eluting stents. This was illustrated in an angioscopic study of 37 consecutive stented lesions (15",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stents and 22 bare metal stents) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/67\">",
"     67",
"    </a>",
"    ]. The following findings were noted on angioscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neointimal coverage was complete in all 22 bare-metal stents. In contrast, neointimal coverage was complete in only 2 of the 15",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stents and three had essentially no coverage.",
"     </li>",
"     <li>",
"      Thrombi were present in eight stented segments, none of which was seen on angiography. Thrombi were more common with incomplete neointimal coverage (5 of 13 versus 3 of 24 stents with complete neointimal coverage).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delayed neointimal coverage with drug-eluting stents prolongs the period of high risk for stent thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H12#H12\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Very late stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949684\">",
"    <span class=\"h3\">",
"     Coronary bypass graft surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioscopic evaluation of saphenous vein bypass grafts (SVG) has added new information regarding the causes of graft failure and potentially effective preventative therapies. In one study, 31 SVGs were assessed and 15 had both yellow plaque and thrombi, whereas in the remaining 16 SVGs the intima was clear white. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949691\">",
"    <span class=\"h3\">",
"     Cardiac transplant vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA has provided significant information concerning the coronary vasculopathy, which commonly occurs in cardiac allografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Although contrast angiography is the current \"gold standard\" for diagnosing allograft vasculopathy, it underestimates its presence when correlated with pathologic examination. One study, for example, compared CA with quantitative angiography and intracoronary ultrasound in 29 consecutive cardiac transplant recipients examined one to four years after cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/69\">",
"     69",
"    </a>",
"    ]. Angioscopy demonstrated pigmented (yellow) or nonpigmented (white) plaques in 79 percent of patients, and coronary stenoses in 24 percent. In contrast, angiography detected plaques in only 10 percent, and stenoses in only 3 percent. The frequency of plaques and stenoses with intracoronary ultrasound was similar to angioscopy. However, only angioscopy provided information about luminal surface morphology and plaque pigmentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949698\">",
"    <span class=\"h2\">",
"     Research applications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949706\">",
"    <span class=\"h3\">",
"     Mechanism of acute coronary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA has contributed to the understanding of the mechanisms underlying acute coronary syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In one report, angioscopy was performed in 86 patients presenting with stable or unstable angina, or an acute or old myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/71\">",
"     71",
"    </a>",
"    ]. Thrombus was present in 100 percent of patients with an acute myocardial infarction, 90 percent with unstable angina, but none with stable angina or old myocardial infarction. The thrombus was usually occlusive in those with an acute myocardial infarction (79 percent), but not in patients with unstable angina (10 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949713\">",
"    <span class=\"h4\">",
"     Evaluation of thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative insensitivity of angiography techniques for thrombi may be explained by the inherent limitations of a contrast \"lumenogram\" of a tortuous, three-dimensional structure viewed in two dimensions. Detection of intracoronary thrombus by angiography requires that the thrombus be large enough to displace contrast material and appear as a \"filling defect\" or a contrast stain in the vessel. The specificity of angiography for detecting intracoronary thrombi is also weakened by the observation that not all angiographic filling defects are thrombi.",
"   </p>",
"   <p>",
"    By comparison, angioscopic detection of a red thrombus is based upon color and texture discrimination and does not rely upon a \"mass effect.\" Small quantities of red thrombus are easily seen against the white or yellow background of the vessel wall. However, the angioscopic identification of intracoronary thrombus is subjective. It requires that the operator have some experience to reliably distinguish red thrombi from other intravascular features which are red:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombi may occur as red intraluminal masses that are fixed to the vessel wall; they are distinguished from stagnant blood in the lumen by their globular, gelatinous texture and their inability to be detached from the vessel wall with a flush solution.",
"     </li>",
"     <li>",
"      Mural thrombi appear as patches of red material fixed to the surface of the vessel wall, analogous to a red carpet on a white or yellow floor. The surface texture of a mural thrombus commonly has a \"woven\" appearance which is not glistening or shiny. It is possible that an inexperienced observer could confuse mural thrombi with either an intramural hematoma or a vessel wall abrasion. However, intramural hematomas have the distinctive appearance of a deep bruise, with a dull, dusky, red color below the smooth glistening surface of the vessel intima. Abrasions of the vessel wall, on the other hand, appear as linear scratches or red streaks on the surface of the artery in contrast to the confluent patches of red thrombus.",
"     </li>",
"     <li>",
"      Angioscopy, by depicting both color and texture, can readily distinguish white or yellow plaque fragments protruding into the vessel lumen from red thrombus. However, the ability of angioscopy to differentiate \"white\" thrombus and other &ldquo;white&rdquo; tissue elements is limited. The angioscopic distinguishing feature of these white intraluminal masses is their shape and texture. Tissue fragments or dissection flaps usually demonstrate sharp, angular margins analogous to tattered white bed sheets on a clothesline blowing in the wind, whereas white thrombi (platelet aggregates and fibrin strands) are globular masses with fuzzy, indistinct borders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Color differences in thrombus may reflect differences in composition due to variations in age or the presence or absence of blood flow. Red thrombi contain an abundance of fibrin mixed with erythrocytes and platelets, whereas white thrombi are platelet-rich. The color of the thrombus shifts progressively toward a pale, whitish color as organization progresses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These color differences may be observed via angioscopy among patients with varying acute coronary syndromes. One series evaluated the physical appearance of the thrombus in 15 and 16 patients with unstable angina and acute ST elevation myocardial infarction, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/74\">",
"     74",
"    </a>",
"    ]. Coronary thrombus was present in 93 percent of patients; the thrombi usually had a grayish-white color (ie, platelet-rich) in patients with unstable angina but was predominantly red (ie, fibrin-rich) in those with acute myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949720\">",
"    <span class=\"h4\">",
"     Differences in plaques",
"    </span>",
"   </p>",
"   <p>",
"    The color of plaque may vary among patients with different acute syndromes. Plaques in patients with acute myocardial infarction can be classified into two color types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Xanthomatous plaque (yellowish), which cannot be recognized with angiography, is more common in patients with acute myocardial infarction and unstable angina than in those with old myocardial infarction and stable angina [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/71,75\">",
"       71,75",
"      </a>",
"      ]; such plaques are found in all three major coronary arteries, suggesting that the development of these vulnerable plaques is a pan-coronary process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/76\">",
"       76",
"      </a>",
"      ]. These plaques often have an irregular intimal surface due to plaque rupture, ulceration, and intimal flap.",
"     </li>",
"     <li>",
"      Smooth, white plaques are observed in patients with old myocardial infarction and stable angina.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences in plaque composition are associated with varying degrees of stability. Xanthomatous plaque is likely to have a high concentration of cholesterol at its base and the fibrous cap overlying the lipid core may be thin. Plaque with high concentration of lipid and a thin fibrous cap may be easily cracked by increased shear force at the level of the stenosis and by acute changes in coronary tone or exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/77\">",
"     77",
"    </a>",
"    ]. By comparison, white plaques are less likely to rupture since the increased fibrous content over the lipid core provides stability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949727\">",
"    <span class=\"h4\">",
"     Identification of vulnerable plaque",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since yellow plaque is more common in acute coronary syndromes compared with stable angina, the presence of yellow plaque on angioscopy in patients with stable angina may predict the future occurrence of an acute coronary event. This hypothesis was examined in a study of 157 patients with stable angina pectoris who underwent CA; 39 had yellow plaques and 118 had white plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/78\">",
"     78",
"    </a>",
"    ]. At 12 months, acute coronary events, confirmed by angioscopy to be the result of thrombus arising from the ruptured culprit plaque, were much more frequent in patients with yellow plaques (28 versus 3 percent). The increase in risk was primarily due to glistening yellow plaques (69 versus 8 percent in those not glistening). Angioscopy can also be used to assess potential therapies to reduce the risk of vulnerable plaque. In a study testing the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    for the stabilization of vulnerable plaque [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/79\">",
"     79",
"    </a>",
"    ], therapy changed lesions from yellow to white, suggesting plaque stabilization. To make potential analysis of vulnerable plaque more accurate, quantitative measurement of its color has also been attempted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949734\">",
"    <span class=\"h3\">",
"     Fibrinolytic therapy",
"    </span>",
"   </p>",
"   <p>",
"    Thrombus overlying disruption in the fibrous cap of an atherosclerotic plaque is considered to be the cause of acute myocardial infarction and unstable angina. Since fibrinolytic therapy is not effective in all patients with these findings, angioscopy has been used to help understand those factors that determine whether such therapy will be beneficial. In one study, for example, the efficacy of fibrinolytic therapy in 25 patients with acute myocardial infarction and 10 with unstable angina was correlated with the type of plaque observed with angioscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/27/34234/abstract/81\">",
"     81",
"    </a>",
"    ]. Red thrombi were found in all patients with an acute infarction, but in only two with unstable angina; the remaining eight patients had white thrombi. Compared to the group with red thrombi, fibrinolytic therapy was significantly less effective in patients with white thrombi (25 versus 69 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949748\">",
"    <span class=\"h2\">",
"     Limitations of coronary angioscopy (CA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the technology of CA has been available for more than 15 years, it is used infrequently and mainly as a research tool, rather than an adjunct to routine clinical care. The reasons for its limited use are several:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CA is a somewhat cumbersome technique requiring significant increases in the time of the case.",
"     </li>",
"     <li>",
"      CA can only be safely utilized in coronary arteries at least 2.5 mm in diameter, which limits its use in smaller vessels.",
"     </li>",
"     <li>",
"      The requirement to deploy a proximal occluding balloon causes unnecessary trauma to a proximal segment of the vessel that may contribute to future restenosis. It also results in temporary occlusive coronary ischemia that may be painful and even detrimental to the patient.",
"     </li>",
"     <li>",
"      Many patients with existing collateral coronary circulation produce enough back-flow of blood distal to the occluding balloon that a clear blood-free image cannot be obtained.",
"     </li>",
"     <li>",
"      A complication called \"wire-trapping\", which results from a loop formation of the guidewire between the two monorail wire channels of the angioscope, may occur. It can occur when the fiber bundle is withdrawn and the coils of the guidewire catch on the tip of the angioscope. This can potentially create dissection or result in an unwanted loss of the guidewire from the vessel. It can be avoided with careful fluoroscopic monitoring during catheter manipulation. When wire-trapping occurs, it may be corrected by extending the fiber bundle first and then withdrawing it carefully under fluoroscopic control.",
"     </li>",
"     <li>",
"      With the availability of intracoronary ultrasound and, more recently, optical coherence tomography, the added information provided by CA is not necessary in many instances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239644785\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intravascular imaging techniques of optical coherence tomography (OCT), intravascular ultrasound (IVUS), and coronary angioscopy (CA) are used to provide information above and beyond that of x-ray coronary angiography. (See",
"      <a class=\"local\" href=\"#H4683151\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal clinical applications for IVUS are guiding coronary interventions and clarifying ambiguous or indeterminate x-ray angiography. (See",
"      <a class=\"local\" href=\"#H321554924\">",
"       'IVUS clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No clinical indications for OCT imaging are established. Our experts believe that OCT can be of value in some patients to evaluate the presence and extent of atherosclerosis, the degree of lumen narrowing, and the results of percutaneous coronary intervention. (See",
"      <a class=\"local\" href=\"#H4683306\">",
"       'OCT clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are no established indications for CA, our experts believe that it may be useful for understanding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evaluating several different clinical settings, such as consequences of different interventional cardiology techniques, cardiac transplant vasculopathy, and the pathophysiology of various coronary syndromes.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/1\">",
"      Yock, P, Fitzgerald, P, Popp, R. Intravascular ultrasound. Sci Am Science Med 1995; 2:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/2\">",
"      Fitzgerald PJ, St Goar FG, Connolly AJ, et al. Intravascular ultrasound imaging of coronary arteries. Is three layers the norm? Circulation 1992; 86:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/3\">",
"      Gussenhoven EJ, Essed CE, Lanc&eacute;e CT, et al. Arterial wall characteristics determined by intravascular ultrasound imaging: an in vitro study. J Am Coll Cardiol 1989; 14:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/4\">",
"      Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005; 45:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/5\">",
"      Kawasaki M, Takatsu H, Noda T, et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 2002; 105:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/6\">",
"      Nair A, Kuban BD, Tuzcu EM, et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/7\">",
"      Nishimura RA, Edwards WD, Warnes CA, et al. Intravascular ultrasound imaging: in vitro validation and pathologic correlation. J Am Coll Cardiol 1990; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/8\">",
"      Matsu-ura Y, Kijima Y, Hashimura K, et al. Intravascular ultrasonic evidence by constant cross-sectional area of atherosclerotic plaques during coronary vasomotion in humans. Eur Heart J 1997; 18:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/9\">",
"      Kornowski R, Lansky AJ, Mintz GS, et al. Comparison of men versus women in cross-sectional area luminal narrowing, quantity of plaque, presence of calcium in plaque, and lumen location in coronary arteries by intravascular ultrasound in patients with stable angina pectoris. Am J Cardiol 1997; 79:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/10\">",
"      Sheifer SE, Canos MR, Weinfurt KP, et al. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J 2000; 139:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/11\">",
"      Herity NA, Lo S, Lee DP, et al. Effect of a change in gender on coronary arterial size: a longitudinal intravascular ultrasound study in transplanted hearts. J Am Coll Cardiol 2003; 41:1539.",
"     </a>",
"    </li>",
"    <li>",
"     Weissman, NJ, Arora, U, Breall, JA, et al. In vivo gender differences in coronary plaque morphology assessed by intravascular ultrasound (abstract). J Am Coll Cardiol 1997; 198A.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/13\">",
"      Mintz GS, Popma JJ, Pichard AD, et al. Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions. Circulation 1996; 93:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/14\">",
"      Ziada KM, Tuzcu EM, De Franco AC, et al. Intravascular ultrasound assessment of the prevalence and causes of angiographic \"haziness\" following high-pressure coronary stenting. Am J Cardiol 1997; 80:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/15\">",
"      Bocksch W, Schartl M, Beckmann S, et al. Safety of intracoronary ultrasound imaging in patients with acute myocardial infarction. Am J Cardiol 1998; 81:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/16\">",
"      Tuzcu EM, Berkalp B, De Franco AC, et al. The dilemma of diagnosing coronary calcification: angiography versus intravascular ultrasound. J Am Coll Cardiol 1996; 27:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/17\">",
"      Mintz GS, Painter JA, Pichard AD, et al. Atherosclerosis in angiographically \"normal\" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 25:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/18\">",
"      St Goar FG, Pinto FJ, Alderman EL, et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: an in vivo comparison with quantitative angiography. J Am Coll Cardiol 1991; 18:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/19\">",
"      Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/20\">",
"      von Birgelen C, Mintz GS, de Vrey EA, et al. Atherosclerotic coronary lesions with inadequate compensatory enlargement have smaller plaque and vessel volumes: observations with three dimensional intravascular ultrasound in vivo. Heart 1998; 79:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/21\">",
"      von Birgelen C, Mintz GS, de Vrey EA, et al. Successful directional atherectomy of de novo coronary lesions assessed with three-dimensional intravascular ultrasound and angiographic follow-up. Am J Cardiol 1997; 80:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/22\">",
"      Berglund H, Luo H, Nishioka T, et al. Highly localized arterial remodeling in patients with coronary atherosclerosis: an intravascular ultrasound study. Circulation 1997; 96:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/23\">",
"      Timmis SB, Burns WJ, Hermiller JB, et al. Influence of coronary atherosclerotic remodeling on the mechanism of balloon angioplasty. Am Heart J 1997; 134:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/24\">",
"      Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/25\">",
"      Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010; 31:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/26\">",
"      Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991; 254:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/27\">",
"      Michelson A, Morley E. On the relative motion of the earth and the luminiferous aether. Philos Mag 1887; S5:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/28\">",
"      Yun S, Tearney G, Bouma B, et al. High-speed spectral-domain optical coherence tomography at 1.3 mum wavelength. Opt Express 2003; 11:3598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/29\">",
"      Chinn SR, Swanson EA, Fujimoto JG. Optical coherence tomography using a frequency-tunable optical source. Opt Lett 1997; 22:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/30\">",
"      Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. JACC Cardiovasc Imaging 2008; 1:752.",
"     </a>",
"    </li>",
"    <li>",
"     Optical coherence tomography in cardiovascular research, 1st ed, Regar E, van Leeuwn AMGJ, Serruys PW (Eds), Informa Healthcare, London 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/32\">",
"      Davlouros P, Damelou A, Karantalis V, et al. Evaluation of culprit saphenous vein graft lesions with optical coherence tomography in patients with acute coronary syndromes. JACC Cardiovasc Interv 2011; 4:683.",
"     </a>",
"    </li>",
"    <li>",
"     Okamura T, Gonzalo N, Gutierrez Chico JL, et al. Does the second generation OCT improve safety and feasibility in clinical practice? A single center experience. Journal of the American College of Cardiology 2010; 55(A202):E1906.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/34\">",
"      Imola F, Mallus MT, Ramazzotti V, et al. Safety and feasibility of frequency domain optical coherence tomography to guide decision making in percutaneous coronary intervention. EuroIntervention 2010; 6:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/35\">",
"      Kawasaki M, Bouma BE, Bressner J, et al. Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll Cardiol 2006; 48:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/36\">",
"      Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary intima--media thickness by optical coherence tomography: comparison with intravascular ultrasound. Circ J 2005; 69:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/37\">",
"      Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/38\">",
"      Gonzalo N, Tearney GJ, Serruys PW, et al. Second-generation optical coherence tomography in clinical practice. High-speed data acquisition is highly reproducible in patients undergoing percutaneous coronary intervention. Rev Esp Cardiol 2010; 63:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/39\">",
"      Low AF, Kawase Y, Chan YH, et al. In vivo characterisation of coronary plaques with conventional grey-scale intravascular ultrasound: correlation with optical coherence tomography. EuroIntervention 2009; 4:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/40\">",
"      Kume T, Okura H, Yamada R, et al. Frequency and spatial distribution of thin-cap fibroatheroma assessed by 3-vessel intravascular ultrasound and optical coherence tomography: an ex vivo validation and an initial in vivo feasibility study. Circ J 2009; 73:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/41\">",
"      Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006; 97:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/42\">",
"      Cilingiroglu M, Oh JH, Sugunan B, et al. Detection of vulnerable plaque in a murine model of atherosclerosis with optical coherence tomography. Catheter Cardiovasc Interv 2006; 67:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/43\">",
"      Tanaka A, Imanishi T, Kitabata H, et al. Distribution and frequency of thin-capped fibroatheromas and ruptured plaques in the entire culprit coronary artery in patients with acute coronary syndrome as determined by optical coherence tomography. Am J Cardiol 2008; 102:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/44\">",
"      Chia S, Raffel OC, Takano M, et al. Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study. Coron Artery Dis 2008; 19:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/45\">",
"      Tearney GJ, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 2003; 107:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/46\">",
"      Vancraeynest D, Pasquet A, Roelants V, et al. Imaging the vulnerable plaque. J Am Coll Cardiol 2011; 57:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/47\">",
"      Regar E, van Beusekom HM, van der Giessen WJ, Serruys PW. Images in cardiovascular medicine. Optical coherence tomography findings at 5-year follow-up after coronary stent implantation. Circulation 2005; 112:e345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/48\">",
"      Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 2003; 89:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/49\">",
"      Gonzalo N, Garcia-Garcia HM, Serruys PW, et al. Reproducibility of quantitative optical coherence tomography for stent analysis. EuroIntervention 2009; 5:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/50\">",
"      Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010; 31:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/51\">",
"      Guagliumi G, Costa MA, Sirbu V, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 2011; 123:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/52\">",
"      Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/53\">",
"      Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012; 59:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/54\">",
"      Prati F, Guagliumi G, Mintz GS, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J 2012; 33:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/55\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/56\">",
"      Regar E, van Soest G, Bruining N, et al. Optical coherence tomography in patients with acute coronary syndrome. EuroIntervention 2010; 6 Suppl G:G154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/57\">",
"      Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography patterns of stent restenosis. Am Heart J 2009; 158:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/58\">",
"      Siegel RJ, Ariani M, Fishbein MC, et al. Histopathologic validation of angioscopy and intravascular ultrasound. Circulation 1991; 84:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/59\">",
"      den Heijer P, Foley DP, Hillege HL, et al. The 'Ermenonville' classification of observations at coronary angioscopy--evaluation of intra- and inter-observer agreement. European Working Group on Coronary Angioscopy. Eur Heart J 1994; 15:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/60\">",
"      Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J 1989; 117:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/61\">",
"      White CJ, Ramee SR, Mesa JE, Collins TJ. Percutaneous coronary angioscopy in patients with restenosis after coronary angioplasty. J Am Coll Cardiol 1991; 17:46B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/62\">",
"      Strumpf RK, Heuser RR, Eagan JT Jr. Angioscopy: a valuable tool in the deployment and evaluation of intracoronary stents. Am Heart J 1993; 126:1204.",
"     </a>",
"    </li>",
"    <li>",
"     Guagliumi, G, Valsecchi, O, Tespili, M, et al. Serial angioscopic assessment of coronary stent lining with antiplatelet or anticoagulant therapy (abstract). J Am Coll Cardiol 1995; 196A.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/64\">",
"      Yamamoto M, Okamatsu K, Inami S, et al. Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy. Am Heart J 2009; 158:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/65\">",
"      Teirstein PS, Schatz RA, Wong SC, Rocha-Singh KJ. Coronary stenting with angioscopic guidance. Am J Cardiol 1995; 75:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/66\">",
"      Ueda Y, Nanto S, Komamura K, Kodama K. Neointimal coverage of stents in human coronary arteries observed by angioscopy. J Am Coll Cardiol 1994; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/67\">",
"      Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/68\">",
"      Hara M, Nishino M, Taniike M, et al. High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent. Am Heart J 2010; 159:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/69\">",
"      Ventura HO, White CJ, Jain SP, et al. Assessment of intracoronary morphology in cardiac transplant recipients by angioscopy and intravascular ultrasound. Am J Cardiol 1993; 72:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/70\">",
"      Mehra MR, Ventura HO, Jain SP, et al. Heterogeneity of cardiac allograft vasculopathy: clinical insights from coronary angioscopy. J Am Coll Cardiol 1997; 29:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/71\">",
"      Mizuno K, Miyamoto A, Satomura K, et al. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet 1991; 337:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/72\">",
"      de Feyter PJ, Ozaki Y, Baptista J, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation 1995; 92:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/73\">",
"      Pearson TA, Dillman J, Solez K, Heptinstall RH. Monoclonal characteristics of organising arterial thrombi: Significance in the origin and growth of human atherosclerotic plaques. Lancet 1979; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/74\">",
"      Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/75\">",
"      Thieme T, Wernecke KD, Meyer R, et al. Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes. J Am Coll Cardiol 1996; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/76\">",
"      Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001; 37:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/77\">",
"      Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/78\">",
"      Uchida Y, Nakamura F, Tomaru T, et al. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina. Am Heart J 1995; 130:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/79\">",
"      Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol 2003; 42:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/27/34234/abstract/80\">",
"      Okada K, Ueda Y, Oyabu J, et al. Plaque color analysis by the conventional yellow-color grading system and quantitative measurement using LCH color space. J Interv Cardiol 2007; 20:324.",
"     </a>",
"    </li>",
"    <li>",
"     Mizuno, K, Etsuda, H, Nagai, T, et al. Differential sensitivity of white and red coronary thrombi to thrombolytic therapy (abstract). J Am Coll Cardiol 1994; 452A.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16536 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-84E1ECB1DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34234=[""].join("\n");
var outline_f33_27_34234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H239644785\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4683151\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H321555002\">",
"      Arterial wall structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H321553541\">",
"      INTRAVASCULAR ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H321553548\">",
"      Technology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H321553583\">",
"      The IVUS image",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H321553590\">",
"      - Ultrasonic image of an atherosclerotic plaque",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H321553604\">",
"      - Men versus women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H321553611\">",
"      - Comparison with coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H321553618\">",
"      Diffuse lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H321553625\">",
"      Complex luminal shapes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H321553632\">",
"      Compensatory enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H321554924\">",
"      IVUS clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H321552326\">",
"      OPTICAL COHERENCE TOMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4683160\">",
"      Technology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683168\">",
"      - Imaging principle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683177\">",
"      - Time domain OCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683193\">",
"      - Fourier domain OCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4683210\">",
"      OCT imaging technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683218\">",
"      - OCT imaging catheters and imaging procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683227\">",
"      - Patient and lesion selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683236\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683245\">",
"      - Concomitant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4683254\">",
"      The OCT image",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683262\">",
"      - Normal coronary morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683271\">",
"      - Atherosclerotic plaques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683288\">",
"      - Assessment of acute stent placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683297\">",
"      - Assessment of long-term stent outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4683306\">",
"      OCT clinical applications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683315\">",
"      - Patients with ACS and angiographically unclear culprit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4683324\">",
"      - Assessment of stent failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12949544\">",
"      CORONARY ANGIOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949551\">",
"      Imaging technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949572\">",
"      - Lesion selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949579\">",
"      Correlation with histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949586\">",
"      The CA image",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949593\">",
"      - Normal coronary artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949600\">",
"      - Abnormal coronary findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949607\">",
"      Atheroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949614\">",
"      Thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949621\">",
"      Dissections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949628\">",
"      Subintimal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949635\">",
"      Luminal narrowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949642\">",
"      Restenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949649\">",
"      Stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949656\">",
"      CA clinical applications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949677\">",
"      - Coronary stent implantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949684\">",
"      - Coronary bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949691\">",
"      - Cardiac transplant vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949698\">",
"      Research applications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949706\">",
"      - Mechanism of acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949713\">",
"      Evaluation of thrombi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949720\">",
"      Differences in plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12949727\">",
"      Identification of vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12949734\">",
"      - Fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949748\">",
"      Limitations of coronary angioscopy (CA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239644785\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/16536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16536|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/1/24593\" title=\"diagnostic image 1A\">",
"      IVUS image coronary artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/20/6464\" title=\"diagnostic image 1B\">",
"      IVUS extent coronary calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/15/43248\" title=\"diagnostic image 2\">",
"      IVUS coronary artery plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/18/17696\" title=\"diagnostic image 3\">",
"      Coronary artery dissection IVUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/42/20143\" title=\"diagnostic image 4\">",
"      IVUS diffuse coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/15/38143\" title=\"diagnostic image 5\">",
"      IVUS tranplanted heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/19/38200\" title=\"diagnostic image 6\">",
"      Coronary artery thickening OCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/6/6249\" title=\"diagnostic image 7\">",
"      Coronary artery with dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/50/1831\" title=\"diagnostic image 8\">",
"      OCT in acute MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16536|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/61/30672\" title=\"figure 1\">",
"      IVUS transducers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/0/38927\" title=\"figure 2A\">",
"      IVUS technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7167\" title=\"figure 2B\">",
"      IVUS catheter insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/20/35137\" title=\"figure 3\">",
"      VH of atherosclerotic plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/36/7759\" title=\"figure 4\">",
"      IVUS angiography comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/53/35665\" title=\"figure 5\">",
"      IVUS artery remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/1/40978\" title=\"figure 6\">",
"      Comparison of OCT and IVUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/59/25530\" title=\"figure 7\">",
"      OCT plaque characterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16536|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/31/8693\" title=\"picture 1\">",
"      OCT system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/36/5704\" title=\"picture 2\">",
"      Normal coronary artery OCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/44/38600\" title=\"picture 3\">",
"      Coronary artery after stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/39/27256\" title=\"picture 4\">",
"      Coronary artery after DES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/44/17097\" title=\"picture 5\">",
"      Coronary artery after stent ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/18/35116\" title=\"table 1\">",
"      Comparison of coronary diagnostic techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34773?source=related_link\">",
"      Coronary artery stent types in development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20729?source=related_link\">",
"      Pathology and pathogenesis of the vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29479?source=related_link\">",
"      Quantitative coronary angiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24165?source=related_link\">",
"      Quantitative coronary angiography: Technical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_27_34235="Symptoms and sequelae of date rape";
var content_f33_27_34235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible symptoms and sequelae of date or acquaintance rape",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Disturbances in sleep (eg, taking more than 20 minutes to fall asleep, nightmares)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in appetite; less interest in eating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatic reactions (eg, chronic pelvic pain, recurrent abdominal pain, chronic headache, multiple physical complaints)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressive symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suicidality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of post-traumatic stress disorder (emotional numbing, diminished interest in everyday activities, detachment from others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric or behavior problems that usually are found in the other gender (eg, eating disorders in boys or fighting in girls)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased self-esteem, self-worth, and/or confidence in their sense of judgment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty maintaining relationships",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexual dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol or substance use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased sexual negotiation skills (may lead to pregnancy or sexually transmitted infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For male victims: Fragility of sense of masculinity and confusion about sexual orientation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34235=[""].join("\n");
var outline_f33_27_34235=null;
var title_f33_27_34236="Birth attendant home birth";
var content_f33_27_34236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Birth attendant and race/ethnicity, US residential births, 2009",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medical doctor or doctor of osteopathy",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Certified nurse midwife",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other midwife",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        20.6",
"       </td>",
"       <td>",
"        43.6",
"       </td>",
"       <td>",
"        31.6",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <strong>",
"         29,981",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White, non-Hispanic",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        21.6",
"       </td>",
"       <td>",
"        47.3",
"       </td>",
"       <td>",
"        28.4",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <strong>",
"         25,358",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Black, non-hispanic",
"       </td>",
"       <td>",
"        20.2",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        55.8",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <strong>",
"         1781",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hispanic",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        38.5",
"       </td>",
"       <td>",
"        38.5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <strong>",
"         2001",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        All other",
"       </td>",
"       <td>",
"        9.6",
"       </td>",
"       <td>",
"        17.5",
"       </td>",
"       <td>",
"        39.1",
"       </td>",
"       <td>",
"        33.8",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <strong>",
"         841",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Number*",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1299",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6119",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         13,321",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9242",
"        </strong>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <strong>",
"         29,981",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excludes cases where attendant or race/ethnicity is unspecified.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: National Center for Health Statistics. VitalStats: Birth data 2010 state and county files. Available at:",
"     <a href=\"file://www.cdc.gov/nchs/VitalStats.htm\" target=\"_blank\">",
"      file://www.cdc.gov/nchs/VitalStats.htm",
"     </a>",
"     (Accessed December 8, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34236=[""].join("\n");
var outline_f33_27_34236=null;
var title_f33_27_34237="High KtV enhances survival ICU";
var content_f33_27_34237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing survival among ICU patients with acute kidney injury according to Kt/V",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival among 512 intensive care unit (ICU) patients with acute renal failure according to urea clearance and ICU score. At a given ICU score, survival was increased in patients with a higher Kt/V urea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Paganini, EP, Tapolyai, M, Goormastic, M, et al, Am J Kidney Dis 1996; 28:S81.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34237=[""].join("\n");
var outline_f33_27_34237=null;
var title_f33_27_34238="Villous adenoma BE";
var content_f33_27_34238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Villous adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema shows a focal region of mucosal irregularity (arrows) caused by a flat villous adenoma. These benign tumors may be pedunculated or sessile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34238=[""].join("\n");
var outline_f33_27_34238=null;
var title_f33_27_34239="Cohen cannula";
var content_f33_27_34239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cohen cannula for uterine manipulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_27_34239=[""].join("\n");
var outline_f33_27_34239=null;
